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ABSTRACT 
 
Couts, Kasey Lyn (Ph.D., Biochemistry) 
Analysis of B-RafV600E Regulated MicroRNAs and Proteins in Melanoma 
Thesis directed by Professor Natalie G. Ahn 
 
Genome sequencing studies have identified oncogenic B-Raf mutations in 
over 70% of all sporadic melanomas.  The B-RafV600E mutation leads to 
elevated kinase activity and constitutive activation of the mitogen-activated 
protein (MAP) kinase signaling pathway, which supports a variety of oncogenic 
functions critical to melanoma formation and progression.  Metastatic melanomas 
are highly resistant to conventional chemotherapeutic treatments, and 
pharmacological inhibitors of B-RafV600E have been incompletely effective in 
pre-clinical studies.  Understanding the global molecular responses to constitutive 
MAP kinase signaling in melanomas would allow the development of more 
effective therapeutics.   
Manipulation of microRNA (miRNA) expression is emerging as an 
important molecular mechanism by which oncogenes can broadly support 
tumorigenesis.  In this study, strategic microarray profiling of melanoma cells 
identified a network of over 25 miRNAs that are controlled by B-RafV600E.  
Functional screening of all regulated microRNAs revealed that many were 
capable of altering cell growth and/or invasion, and I was able to identify 
important melanoma genes that were targeted by one or more B-RafV600E 
miRNA(s).  Interestingly, several genes suppressed by multiple miRNAs were 
iii
direct targets for both induced and repressed miRNAs, suggesting a highly 
complex interaction of co-regulated miRNAs may contribute to overall gene 
regulation.  The strong overlap in targets and functions suggested that B-
RafV600E miRNAs might work cooperatively, and I showed that miRNAs work 
combinatorially to further augment cellular invasion responses. 
Previously, a similar DNA microarray profiling analysis discovered a set 
of axon guidance genes repressed by activated MAP kinase signaling in 
melanoma cells.  I validated one of these genes, semaphorin 3C (sema3C), as 
suppressed by B-RafV600E through a transcriptional mechanism involving the 
co-regulation of TFAP2A, ATF3, and JUN transcription factors.  Functional 
analyses in both primary and metastatic melanoma cell lines using strategies for 
sema3C inhibition or over-expression identified a novel role for this semaphorin 
in melanoma cell migration and invasion, as well as tumor growth and metastasis.  
By using microarray profiling studies to identify global molecular responses to 
activated MAP kinase signaling in melanoma cells, I established multiple 
microRNAs and an axon guidance gene, sema3C, as novel molecular targets 
controlled by B-RafV600E and functionally relevant in melanoma progression.  
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CHAPTER I 
 
INTRODUCTION 
 
Melanoma Biogenesis 
Melanoma is a highly aggressive form of cancer that originates in the skin 
and other pigmented organs.  Although melanoma accounts for only 4% of all 
skin cancers, it is responsible for 80% of all skin cancer-related deaths (Miller and 
Mihm, 2006).  If detected early, it can be surgically excised from the skin with a 
survival rate of greater than 95% (Satyamoorthy and Herlyn, 2002).  However, 
once melanoma metastasizes, it becomes highly resistant to conventional 
chemotherapy, and the median survival rate is only 6 months (Gray-Schopfer et 
al, 2005).  Metastatic melanoma is highly radioresistant and chemoresistant, and 
studies aimed at identifying the genes associated with drug resistance were largely 
unsuccessful (Serrone and Hersey, 1999).  Therefore, further understanding of the 
etiology of the disease is essential for the development of more effective 
therapeutics.     
Melanoma is derived from pigment-producing melanocyte cells, located in 
skin at the epidermal-dermal junction.  The transition of melanocytes into 
melanomas can be classified into several stages, including (i) atypical or 
dysplastic nevi, (ii) radial growth phase (RGP) primary melanomas, (iii) vertical 
growth phase (VGP) primary melanomas, and (iv) metastatic melanoma 
(Bogenrieder and Herlyn, 2002, Figure 1.1).  Conversion of melanocytes into 
melanoma may involve the formation of a benign pigmented lesion, called a 
nevus (Koh, 1991).  Nevi are formed from melanocyte cells that have transitioned 
to a hyperproliferative state by acquiring mutations in protooncogenes such as B-
Raf or N-Ras, but which ultimately undergo senescence and rarely progress into 
melanoma (Mooi and Peeper, 2006; Zaidi et al, 2008; Clark et al, 1984).   
Upon further acquisition of mutations that allow the cells to bypass 
oncogene-induced senescence, cells become transformed but retain low invasive 
potential and therefore appear as RGP tumors, which are largely confined to the 
epidermis and spread laterally into thin tumors (Zaida et al, 2008).  Transition 
into VGP melanoma, where cells become invasive and penetrate into the dermis, 
involves a number of changes in genes which regulate cell adhesion, including 
loss of E-cadherin and gain of N-cadherin cell adhesion receptors, and elevated 
expression of αVβ3 integrin receptors (Danen et al, 1996; Hsu et al, 1996; Danen 
et al, 1994).  Once they have invaded into the dermis, melanoma cells can 
dissociate from the primary tumor and pass through the walls of blood and 
lymphatic vessels, promoting metastasis to lymph nodes and other organs such as 
liver, brain, and lung (Gray-Schopfer et al, 2005).  Metastatic melanomas are 
highly aggressive and have oncogenic molecular changes in cellular apoptosis and 
survival pathways, rendering metastatic melanoma cells resistant to cell death 
following treatment with most chemotherapeutic compounds (Ivanov et al, 2003).         
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Figure 1.1  Melanoma progression is a multi-stage process.
Diagram representing the multiple stages of melanoma progression.  Normal 
melanocyte cells may undergo increased proliferation to form a benign nevus, 
which aquires additional mutations to become transformed into melanoma.  Mela-
noma first spreads laterally in a radial growth phase before invading vertically 
into the dermis and ultimately metastasiszing.  
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mutations occr at a single base change which specifies the amino acid 
substitution, V600E (Davies et al, 2002; Dhomen and Marais, 2007; Brose et al, 
2002).  The cause of this mutation and its potential link to sun-induced UV 
damage are unclear.  Because tumors harboring B-RafV600E occur more 
frequently on areas of the skin which receive intermittent sun exposure and not in 
regions which are completely protected from sun, they lack typical signs of DNA 
damage by UV irradiation found in other types of skin tumors (Cohen et al, 2004; 
Edwards et al, 2004; Maldonado et al, 2003; Gray-Schopfer et al, 2005).  Also, 
B-RafV600E mutations are found in a small percentage of non-skin cancers, 
including thyroid, colorectal, and ovarian cancers (Garnett and Marais, 2004).  
These findings suggest that UV plays a role in promoting B-Raf mutations in 
melanoma through an as yet undiscovered mechanism, and that other events 
besides UV-induced DNA damage are capable of potentiating this mutation in 
tumors in other organs. 
Multiple reports show a high frequency of the B-RafV600E mutation 
throughout all stages of melanoma progression, including benign nevi (Yazdi et 
al, 2003; Loewe et al, 2004; Pollock et al, 2003; Satyamoorthy et al, 2003).  The 
prevalence of B-RafV600E in a high percentage of nevi and the observation that 
cells undergo senescence in these lesions suggests that the B-RafV600E mutation 
by itself is not sufficient to promote melanocyte transformation into melanoma 
(Michaloglou et al, 2005; Miller and Mihm, 2006).  Nevertheless, V600E 
mutations are frequent in nevi and are maintained throughout the various stages of 
melanoma, which implies that B-RafV600E is important for both formation and 
progression of melanoma (Omholt et al, 2003; Yazdi et al, 2003).   
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  Unlike other B-Raf mutations that lead to elevated c-Raf levels, the 
V600E mutation causes elevated kinase activity and constitutive activation of the 
B-Raf/MKK/ERK signaling pathway (Davies et al, 2002; Brose et al, 2002; Wan 
et al, 2004, Figure 1.2B).  Melanomas which do not contain B-RafV600E often 
carry activating mutations in N-Ras (Alsina et al, 2003; Gorden et al, 2003), thus, 
the B-Raf/MKK/ERK signaling pathway is constitutively activated in the majority 
of melanoma cell lines and tissues (Zhuang et al, 2005).  Activated ERK1/2 
signaling is critical for melanoma progression.  Blocking ERK1/2 activity with B-
Raf RNA interference or MKK1/2 inhibition with cell permeable inhibitors or 
anthrax lethal factor protease results in suppressed cell proliferation, decreased 
cell invasion, and increased apoptosis and melanocyte differentiation, the latter 
measured by the expression of enzymes involved in melanin biogenesis 
(Sumimoto et al, 2004; Hingorani et al, 2003; Koo et al, 2002).  Elevated ERK1/2 
signaling also contributes to angiogenesis and allows melanoma cells to evade 
immune surveillance (Sumimioto et al, 2006; Kono et al 2006; Kumar et al, 2007, 
Sharma et al, 2005).   
While a diverse set of functional roles for the MAP kinase pathway has 
been identified in melanoma, very few of the molecular targets linking B-
RafV600E signaling to each function have been characterized.  Active ERK1/2 in 
melanoma has been shown to induce cyclin D1 (CCND1) and repress p27 
(CDKN1B) as a mechanism for inducing cell proliferation, and also suppresses 
apoptosis by inhibiting the activity or expression of the pro-apoptotic effectors, 
TRAIL, BAD, and BIM (Bhatt et al, 2005; Zhang et al, 2008; Eisenmann et al, 
2003; Cartlidge et al, 2008).  The role of the MAP kinase pathway in 
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B-Raf mutations in melanoma 
B-Raf is a central serine/threonine kinase effector in the classical mitogen-
activated protein (MAP) kinase signal transduction cascade.  Signaling cascades 
are responsible for transmitting extracellular signals from the cell surface to the 
nucleus, where they induce changes in gene expression to elicit different cellular 
responses.  The MAP kinase signaling cascade can be activated by growth factors, 
cytokines, and hormones that bind to tyrosine kinase receptors on the cell surface, 
leading to the activation of the small GTPase, Ras, which binds and activates Raf 
protein kinases.  Activated Raf then phosphorylates and activates the dual 
specificity kinase, MKK1/2, and MKK1/2 in turn phosphorylates and activates the 
serine/threonine kinase, ERK1/2 (Lewis et al, 1998; Kyriakis et al, 2000; Figure 
1.2A).  ERK1/2 is capable of phosphorylating a wide range of substrates in 
cytoplasm, nuclear, and membrane compartments, ultimately leading to changes 
in gene expression which drive the cell cycle and cell proliferation, cell 
differentiation, and organismal development (Chen et al, 2001).  There are three 
different Raf isoforms, named A-Raf, B-Raf, and C-Raf (Marais et al, 1997).  All 
three isoforms are recruited to the plasma membrane for activation, but B-Raf is 
the only isoform that can be activated by Ras alone since the other isoforms also 
require activation by tyrosine phosphorylation, catalyzed by Src family kinases 
(Marais et al, 1997; King et al, 2001).  As a result, B-Raf is easier to activate, 
which may underlie the predominant susceptibility of cancers towards mutation of 
this Raf isoform.    
Genome sequencing studies have discovered that oncogenic mutations in 
B-Raf occur in over 70% of all sporadic melanomas, and the majority of these 
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Figure 1.2  MAP kinase signaling in normal cells versus melanomas.
(A)  The classical MAP kinase (MAPK) pathway transmits extracellular signals 
through receptor tyrosine kinases and the B-Raf/MKK/ERK cascade to elicit 
different cellular responses.  (B)  In melanoma, the B-RafV600E mutation causes 
constitutive activation of the B-Raf/MKK/ERK cascade and supports a varity of 
oncogenic functions that are critical to melanoma progression.
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angiogenesis is less well defined, although B-RafV600E induces expression of 
HIF1α and VEGF, which may promote blood vessel formation and recruitment 
(Kumar et al, 2007; Sharma et al, 2005).  The induction of integrin β3 and various 
matrix metalloproteinases (MMPs) provides a link between oncogenic B-
RafV600E and cell invasion, and the ability of B-RafV600E to block the release 
of immunosuppresive cytokines may contribute to its control of immune cell 
evasion (Smalley 2010; Sumimoto et al, 2006).  Identification of cellular targets 
for B-Raf/MKK/ERK which are important for processes such as angiogenesis and 
immune evasion are further complicated by the lack of basic knowledge about the 
molecular components that function in these pathways.  Therefore, a method for 
discovering targets of B-RafV600E not based on previously established pathways 
would allow the identification of new regulatory mechanisms and lead to a better 
understanding of how this pathway promotes melanoma biogenesis.          
 
Global analysis of B-RafV600E targets 
Despite the pivotal role of oncogenic B-Raf/MKK/ERK signaling in 
melanoma progression, pharmacological inhibitors of B-Raf and MKK1/2 have 
been incompletely effective in pre-clinical studies.  Inhibitors of these kinases 
strongly suppress cell proliferation and induce apoptosis in vitro, but are unable to 
induce similar effects on mouse tumor xenografts in vivo (King et al, 2006; 
Smalley et al, 2006; Haass et al, 2008; Smalley and Flaherty, 2009).  Elucidating 
the global molecular responses to activated ERK1/2 would provide better 
understanding of this complex pathway in melanoma and aid in the development 
of more effective therapeutic strageies towards B-RafV600E in melanoma. 
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 Over the last decade, microarray profiling has emerged as a useful and 
accessible strategy for analyzing global change in gene expression.  By “printing” 
oligonucleotide probes onto solid supports (microarrays) and hybridizing with 
fluorescently labelled cDNA prepared from isolated mRNA templates, signals 
which report abunances of more than 20,000 mRNAs can be quantified 
simultaneously.  This technique can be used to profile global gene expression in 
cell lines or tissues from normal, cancerous, or drug-treated samples within a 
single experiment.  Statistical comparison of the intensity measurements and how 
they differ identifies all genes which are differentially expressed between cellular 
states.  This eliminates the need for speculation about which genes in a pathway 
are affected by various cell perturbations, and allows the discovery of genes 
which function in novel ways within established pathways.   
 Although microarray analysis is a powerful tool, there are many 
drawbacks and challenges associated with this technique, including variations 
between biological samples, design and technical execution of each experiment, 
and statistical analysis of the data (extensively reviewed by Kim et al, 2010).  
Subsequently, the results of different studies investigating the same biological 
phenomenon can be widely inconsistent, and sometimes show very little overlap 
in genes identified as significantly altered.  Six separate studies have used 
microarray profiling to monitor global gene responses to B-RafV600E mutations 
in melanoma.  Independent analysis of the datasets identified no genes which 
overlapped between the studies, suggesting that the results of individual studies 
are likely sample-group specific (Hoek et al, 2006).  One major caveat of these 
studies was the comparison of melanoma cells harboring mutant V600E B-Raf vs 
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wild type B-Raf, derived from different patient specimens.  As previously 
mentioned, tumors with wild type B-Raf often harbor other compensatory 
mutations that ultimately lead to constitutively activated ERK1/2.  Thus, it was 
difficult to perform a direct analysis of B-RafV600E targets from these datasets, 
and no experimental condition allowed the identification of a biologically relevant 
gene signature. 
 In order to identify targets directly responsive to B-Raf/MKK/ERK 
signaling in melanomas, our laboratory developed a strategy for microarray 
profiling based on the suppression of ERK1/2 activity in cells by treatment with a 
small molecule inhibitor of MKK1/2 (U0126, Favata et al, 1998).  First, 
microarray expression profiles of normal melanoctye and B-RafV600E-
containing melanoma cells are compared to identifiy genes differentially 
expressed in the melanomas.  This comparison includes genes which change 
expression due to the presence of B-RafV600E or other mutations and altered 
signaling pathways.  Therefore, in a second experiment, the melanoma cells are 
treated with U0126 and analyzed for the genes which respond to the inhibitor in a 
manner opposite to the direction of change seen upon comparing melanocyte to 
melanoma cells.  Inhibiting activated ERK1/2 in each cell line enabled direct 
identification of targets responsive to the B-Raf/MKK/ERK pathway and 
eliminated the complexity which arises due to variation between cell lines.  In 
Chapter II, I describe a similar two-step profiling strategy to identify miRNAs 
regulated by B-RafV600E in melanoma cells.  In Chapter III, I describe use of the 
same strategy in a DNA microarray screen to establish semaphorin 3C as a novel 
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target of B-Raf signaling and gain new insight into the regulation and function of 
this axon guidance gene family member in melanoma.   
 
MicroRNAs and cancer 
 MicroRNAs (miRNAs) are short, non-coding RNAs which generally 
function as negative regulators of gene expression.  The basic steps in the 
biogenesis pathway of miRNAs have been reasonably well characterized (Figure 
1.3).  Primary precursor miRNAs (pri-miRNAs) are transcribed from either 
intergenic or intronic regions of DNA, catalyzed mostly by RNA polymerase II 
(Lee et al, 2004).  These transcripts can be many kilobases long and contain a 
number of stem-loop hairpin structures.  Pri-miRNAs are first processed into 
small hairpins termed “pre-miRNAs” by the Microprocessor complex, which 
consists of the class 2 ribonuclease III enzyme, Drosha, and its protein cofactor , 
DGCR8 (Lee et al, 2002; Lanthaler et al, 2004; Lee et al, 2003; Gregory et al, 
2004).  For a small number of miRNAs, pre-miRNAs are generated by the 
microprocessor complex from other RNA sources, including mirtrons and short 
hairpin RNAs (Babiarz et al, 2008).  The pre-miRNAs are then exported to the 
cytoplasm via the nuclear transport receptor, exportin 5 (Yi et al, 2003; Bohnsack 
et al, 2004; Lund et al, 2004).   
After reaching the cytoplasm, pre-miRNAs are cleaved into ~22-nt 
duplexes by another ribonuclease III enzyme, Dicer.  One strand of the duplex, 
called the mature miRNA or “guide” strand, is loaded onto an argonaute (Ago) 
protein complex (Schwarz et al, 2006; Bernstein et al, 2001).  This forms the 
RNA-induced silencing complex (RISC), composed of Ago, the HIV-I TAR RNA 
11
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Figure 1.3  MicroRNA biogenesis pathway.
MicroRNA primary transcripts (pri-miRNAs) are transcribed by RNA polymerase 
II (RNA pol II) and processed into short hairpins (pre-miRNAs) by the Micropro-
cessor complex.  Pre-miRNAs are transported to the nucleus by the exportin 5 
receptor, where they undergo cleavage into a ~22 nt duplex by the DICER com-
plex.  One of the duplex strands (the mature miRNA) gets loaded onto an Argo-
naute (Ago) protein, subsequenly forming the RNA-induced silencing complex 
(RISC).  RISC binds mRNA 3’UTRs according to partial complimentarity to the 
miRNA strand and silences overall gene expression.
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binding protein (TRBP), and/or a related dsRNA binding protein, PACT 
(Chendrimada et al, 2005; Lee et al, 2006; Maniataki and Mourelatos, 2005).  The 
loaded RISC complex associates with the 3’UTR region of an mRNA molecule, 
based on partially complimentary binding of the miRNA guide strand to the 
mRNA.  Binding of the RISC complex leads to the suppression of translation 
and/or mRNA degradation, resulting in overall reduced gene expression 
(reviewed by Tijsterman and Plasterk, 2004).   
Over 30% of all mRNAs are predicted to be miRNA targets, highlighting 
the significance of miRNAs as a key mechanism for gene regulation (Lewis et al, 
2005; Xie et al, 2005).  Gene regulation through miRNAs is likely complex, since 
an individual miRNA is able to bind and regulate a large number of mRNA 
3’UTRs, and because most 3’UTRs contain recognition sites for many different 
miRNAs.  The ability of miRNAs to simultaneously control the expression of a 
large number of gene targets, including oncogenes and tumor suppressor genes, 
makes them ideal targets for dysregulation in cancer.    
 Recently, miRNAs have emerged as key players in cancer and other 
human diseases.  The first example of aberrant miRNA expression in cancer was 
reported in a study linking a chromosomal deletion in chronic lymphocytic 
leukemia to the loss of expression of two microRNAs, miR-15 and miR-16 (Calin 
et al, 2002).  The new link between miRNAs and cancer heightened interest in 
documenting cancer-miRNA expression relationships, which led to the 
development of microarray platforms for analyzing global changes in miRNA 
expression.  To date, numerous microarray profiling studies have been performed 
in a wide variety of cancers and a large number of miRNAs have been found to be 
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dysregulated in one or more cancers (extensively reviewed by Lee and Dutta, 
2009; Visone and Croce, 2009). 
 Coinciding with their dysregulation in cancers, miRNAs have been shown 
to influence various aspects of cancer cell biology.  They have been shown to 
influence cell proliferation by targeting many cell cycle regulatory genes, such as 
p27, cdk6, cdc25a, and cyclin D2 (le Sage et al, 2007; Johnson et al, 2007; 
Gilliees and Lorimer, 2007; Galardi et al, 2007).  miRNAs also have prominent 
roles in apoptosis through the suppression of prosurvival genes such as Mcl-1 and 
Bcl-2 (Bommer et al, 2007; Mott et al, 2007).  Two miRNAs, miR-21 and miR-
10b, have been strongly linked to enhanced cell invasion and metastasis in many 
cancer types, and the oncogenic miR-17-92 cluster has been associated with 
increased angiogenesis through repression of thrombospondin-1 and connective 
tissue growth factor (Meng et al, 2007; Asangani et al, 2007; Ma et al, 2007; 
Dews et al, 206).  Thus, miRNAs play vital roles in multiple cancer processes and 
their deregulation has significant impact on cancer cell behavior.    
Because the molecular events behind B-RafV600E induced oncogenesis 
are poorly understood, and given that miRNAs have been shown to influence 
many oncogene functions, we hypothesized that deregulation of miRNAs may 
serve as an important mechanism for B-RafV600E-mediatied cell behavior in 
melanomas.  Chapter II describes a study where I use a two-step profiling strategy 
to identify a network of B-RafV600E-regulated miRNAs.  I further investigate the 
functions and gene targets of the miRNAs in this network to characterize their 
role in melanoma progression. 
 
14
Class 3 semaphorins and cancer 
Semaphorin ligand and plexin receptor gene families were originally 
identified as important axon guidance molecules in models for neuronal 
development (Luo et al, 1993; Fujisawa 2004).  Interactions between semaphorins 
and plexins are responsible for transmitting either attracting or repelling cues to 
the extending neuronal axons, thereby determining the direction of axon growth.  
Semaphorins are members of a large extracellular ligand family, consisting of 
secreted or membrane-bound glycoproteins.  They are defined by a characteristic 
N-terminal sema domain and a plexin-semaphorin-integrin (PSI) domain (Koppel 
et al, 1997; Gherardi et al, 2004).  Semaphorins are separated into eight different 
classes based on their amino acid similarity and structural elements, and classes 3-
7 contain all 20 known vertebrate semaphorin ligands (Goodman et al, 1999).  
Class 3 semaphorins are the only vertebrate semaphorins known to be secreted 
from cells, whereas class 4-7 semaphorins are anchored to the membrane through 
unique structural elements, including thrombospondin repeats or 
glycophosphatidylinositol (GPI) plasma membrane anchors (Kruger et al, 2005).  
Semaphorins signal through a large family of receptors known as plexins.  
Plexins are highly conserved transmembrane glycoproteins, and include nine 
vertebrate family members separated into four classes (A, B, C, D) based on 
sequence identity (Tamagnone and Comoglio, 2000).  All semaphorins directly 
bind plexin receptors, with the exception of the secreted class 3 semaphorins.  
Class 3 semaphorins instead bind neuropilin-1 or neuropilin-2 (NRP1/2) co-
receptors and promote the assembly and activation of a receptor complex, 
including NRP-1/2 and either plexin A1 or plexin A2 (PLXNA1/2, Figure 1.4).  
15
Rac1
P
PAK
LIMK
P
cofilin
P
RND
FARP2 PIPK1
PI3K
Akt
RRas
Actin dynamics 
Cell migration
CRMP2
FYN
CDK5 PP
GSK3-βP
FES
NRP1/2
PLXNA1/2
L1CAM
Integrin
α
β
SEMA3
?
Figure 1.4  Signaling pathways downstream of class 3 semaphorins and their 
receptors.
Class 3 semaphorin ligands promote the assembly of SEMA/NRP/PLXNA recep-
tor complexes that signal through multiple kinase pathways to influence actin 
cytoskeleton dynamics and cellular migration.  This figure was adapted from 
Pasterkamp et al, 2003 and Zhou et al, 2008.  
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PLXNA1/2 activation causes dissociation of the FERM, RhoGEF and pleckstrin 
domain protein-2 (FARP2), which leads to subsequent activation of Rac1 through 
a PAK/LIMK1/cofilin pathway, as well as activation of Rnd/R-Ras.  Coupled 
with PLXNA1/2 activation of the non-receptor tyrosine kinases Fyn and Fes, 
which phosphorylate collapsin response mediator protein-2 (CRMP2), these 
signaling pathways converge to promote axon guidance or cell migration by 
controlling cytoskeleton dynamics through the nucleation and polymerization of 
F-actin.  The class 3 semaphorin family members have different affinities for the 
neuropilins and preferentially bind NRP1 and/or NRP2 in order to generate a 
specific functional response.  Additionally, other receptors such as L1CAM or 
NrCAM can associate with this complex, and specify whether the axon response 
will be repulsive or attractive (Tran et al, 2007).     
Although originally discovered in neurons, semaphorins and plexins are 
expressed in numerous cell types and have been linked to cancer and other 
diseases (Tamagnone and Comoglio, 2004; Zhou et al, 2008).  Specifically, class 
3 semaphorins have been identified as major players in controlling cell invasion, 
growth, and angiogenesis in a variety of cancers (reviewed by Gaur et al, 2009).  
Similar to their divergent roles in axon attraction and repulsion, class 3 
semaphorins have been implicated in opposing functions as tumor suppressors 
and oncogenes in cancers.  Generally, semaphorins 3B and 3F behave as tumor 
suppressors, whereas semaphorin 3C, 3E, and 5C are oncogenic (Rizzolio and 
Tamagnone, 2007).  Semaphorin 3B blocks proliferation and survival in lung and 
breast cancer cells, and semaphorin 3F inhibits both angiogeneis and metastasis in 
tumor cells (Castro-Rivera et al, 2004; Tomizawa et al, 2001; Kessler et al, 2004; 
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Bielenberg et al, 2004).  Conversely, semaphorin 3C has been linked to an 
increase in adhesion, invasion, proliferation, and metastasis in prostate and lung 
cancer cells (Martin-Satue et al, 1999; Banu et al, 2006; Herman and Meadows, 
2007).             
Recently, our laboratory applied the two-step microarray profiling strategy 
described above to screen for B-RafV600E gene targets in melanoma.  Axon 
guidance genes comprised the set of genes most strongly repressed by B-
Raf/MKK/ERK signaling in melanoma cells (Argast et al, 2009).  Semaphorin 3C 
was found among this set of genes, and demonstrated the largest gene induction in 
response to MKK1/2 inhibition.  Interestingly, semaphorin 3C has been strongly 
associated with oncogenic phenotypes  in previous cancer studies.  However, due 
to the bifunctional roles of class 3 semaphorins in cancer, we hypothesized that 
semaphorin 3C behaves as a tumor suppressor in melanoma cells.  The focus of 
the study in Chapter III is to validate the control of semaphorin 3C expression by 
B-RafV600E in melanoma cells and determine the functional significance of this 
axon guidance molecule in melanomas.  
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CHAPTER II 
 
B-RafV600E Regulation of MicroRNAs in Melanoma 
 
INTRODUCTION 
  
The prevalance, activating mechanism, and functional significance of the 
oncogenic B-RafV600E mutation in melanoma have been extensively studied 
over the last several years.  However, the molecular targets of oncogenic B-Raf 
signaling which contribute to the disease remain largely unknown.  Identification 
of the molecular determinants that link constitutive B-Raf/MKK/ERK signaling to 
its oncogenic phenotypes in melanoma is crucial for better understanding of 
disease etiology and development of clinical intervention strategies.   
Recently, miRNAs have been identified as key molecular components 
responsible for protein dysregulation and subsequent phenotypic alterations in 
many cancers and diseases.  Manipulation of miRNA expression is emerging as 
an important molecular mechanism by which oncogenes can broadly support 
tumorigenesis.  Studies examining the mechanisms for regulating miRNA 
expression have mainly focused on aberrently expressed transcription factors and 
have identified one or more miRNAs regulated by central factors such as c-Myc, 
MYCN,  and p53 (O’Donnell et al, 2005; Chang et al, 2008; Schulte et al, 2008; 
He et al, 2007).  A handful of studies have addressed correlations in gene 
mutational status with miRNA expression in cancer tissues, including B-Raf in 
melanoma (Caramuta et al, 2010), however these studies often yielded few 
miRNA targets due to extensive complications from patient variation and 
compensatory mutations.  Consequently, the widespread effects of oncogenic 
pathways on global miRNA expression remains largely unexplored. 
In this study, we used strategic microarray profiling on a highly sensitive 
platform to identify miRNAs regulated by B-RafV600E signaling in melanoma 
cells.  Rather than simply comparing normal samples to melanoma samples 
containing the B-RafV600E mutation, we used a two-step microarray screening 
strategy involving U0126, a small molecule inhibitor of MAP kinase kinase 1/2 
(MKK1/2), to directly probe for miRNAs dysregulated by constitutive B-
Raf/MKK/ERK signaling.  Using this strategy, we discovered a network of more 
than 25 miRNAs that were controlled by this oncogenic pathway, accounting for 
greater than 50% of the total miRNAs dysregulated in the melanomas compared 
to melanocytes.  Functional screening of all regulated miRNAs using synthetic 
mimics and inhibitors revealed that over half were capable of altering cell growth 
and/or 3-dimensional invasion, and I was able to identify numerous genes that 
were targeted by one or more B-RafV600E miRNAs.  Interestingly, several of the 
genes targeted by multiple miRNAs (CCND1, CCNE2, LEF-1, ITGB3) were 
direct targets for both induced and repressed miRNAs.  The strong overlap in 
targets and functions suggested that B-RafV600E miRNAs might work 
cooperatively, and I further demonstrated that miRNAs work combinatorially to 
further augment cellular invasion responses.  Overall, these findings highlight the 
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importance of miRNAs in B-RafV600E-mediated control of melanoma biogenesis 
and reveal the significance of analyzing entire miRNA networks in cancer due to 
cross-regulation of both gene targets and functions. 
 
METHODS 
 
Cell Culture 
 Primary melanocyte cell lines NHEM693 and NHEM2493 (Cambrex Bio 
Sciences Walkersville, Walkersville, MD, USA) were cultured in Medium154 
plus Human Melanocyte Growth Supplement (Cascade Biologics, Portland, OR, 
USA).  Melanoma cell lines were a gift from Meenhard Herlyn, Wistar Institute 
(Hsu et al, 1999) and were grown in RPMI (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% FBS (Gemini, West Sacremento, CA, USA) and 
penicillin-streptomycin (100 U/mL).  All cell lines were maintained at 37°C and 
5% CO2.   
 
miRNA Microarray Profiling 
 Melanocyte and melanoma cell lines were plated at pre-determined 
densities in order to achieve ~60% confluency after 48 hours, at which time the 
cells were harvested in 600 µL Buffer RLT Plus (Qiagen) and stored at -80°C.  
For treated melanoma samples, either 0.1% (v/v) dimethyl sulfoxide (DMSO) or 
10 µM U0126 (Promega, Madison, WI, USA) were added to duplicate plates 24 
hours prior to harvesting.  Biological replicate samples were generated from cells 
approximately 2 passages removed.  Total RNA, containing miRNA, was purified 
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using the Qiagen RNeasy Plus kit according to the manufacturer’s Supplementary 
Protocol 1.  MicroRNA microarray profiling was performed using the Thermo 
Scientific Dharmacon platform.  Briefly, 500 ng total RNA was mixed with a 
proprietary, synthetic miRNA spike-in control and samples were fluorescence-
labeled using T4 RNA ligase (Promega, #M1051) and pCp-Cy5.  After 
incubation, a recovery oligonucleotide was added and subsequently passed 
through a p6 column (BioRad) per manufacturer’s instructions.  Thermo Fisher 
miRNA Reference Probe Set, Agilent 2X HI-RPM hybridization buffer, and 25X 
fragmentation buffer were added to each sample and hybridized to Thermo Fisher 
(miRBase 9.0, probes in triplicate) 8 x 15K custom miRNA microarrays 
(Agilent).  Hybridizations were performed in a rotating incubator at 53°C at 12 
RPM for 20 hours.   Slides were washed and scanned on an Agilent Microarray 
Scanner (model G2505B), and data were extracted using Agilent Feature 
Extraction 9.5.1.  Triplicate probe signals were averaged and adjusted for 
background, and the Cy5 (sample) channel was normalized to Cy3 (synthetic 
reference) for each probe.  For each array, the normalized Cy5 signals were scaled 
against spike-in controls to adjust for global labeling bias. “Is-Present” p-values 
were calculated for signals in the Cy5 (sample) channel using a set of background 
(non-specific hybridizing) probes and the Gaussian error function.  A set of 264 
high-confidence probes was defined as those with p-value < 0.05 in 20 of 40 
samples.  This set was used as the basis feature set for inter-array normalization, 
using a mean-centering scaling.  The normalized signals were transformed to 
Log(10) and imported in Microsoft Office Excel 2007 for further analysis. 
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Real-Time Quantitative RT-PCR 
 Melanocyte, melanoma, and treated melanoma samples were prepared as 
described for microarray analysis except cells were lysed in a volume of 1.0 mL 
of Buffer RLT Plus (Qiagen).  Total RNA extraction and real-time RT-PCR using 
absolute quantification were performed by Asuragen, Inc (Austin, TX, USA).  
Briefly, 1.0 ng of total RNA was reverse transcribed using stock ABI Taqman 
miRNA assays (Applied Biosystems) and 3.0 µL of the product was used in a 
subsequent Taqman PCR amplification performed in triplicate on a validated ABI 
7900HT real-time thermocycler.  The Ct value of each reaction was compared to a 
standard curve of synthetic miRNAs with known copy number to generate an 
absolute copy number per ng RNA for each sample.  Standard curves for each 
miRNA assay set were generated from synthetic RNAs diluted in yeast tRNA 
ranging from 500 to 50,000,000 copies per reaction, and all reactions had R2 
values of at least 0.999. 
 
Mimic and Inhibitor Transfections 
 Synthetic mimics and inhibitors (Dharmacon, Thermo Fisher Scientific, 
Lafayette, CO, USA) were reconstituted in 1x RNA buffer to a stock 
concentration of 20 µM.  Cells were transfected in suspension using DMRIE-C 
(Invitrogen) and incubated at 37°C for 5 hours before replacing the media. 
 
WST-1 Cell Growth Assay 
 Cells were transfected with l00 nM mimic or lipid only and incubated for 
24 hours, at which point the cells were then trypsinized, counted, and re-
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suspended to a concentration of 40,000 cells/mL.  A total of 4,000 cells (100 µL) 
of each sample were plated in triplicate on two identical 96-well plates.  Prior to 
reading the plates, a standard curve ranging from ~500 to 50,000 cells was added 
to the plates and incubated for 3 hours.  The plates were then centrifuged at 1,000 
rpm for 5 minutes before removing the media and adding 100 µL of media 
containing WST-1 reagent (Clontech) at a concentration of 60 µL/mL.  Plates 
were incubated at 37°C for 1 hour and then quantified at 450 nm using a 
microplate reader.  The OD reading for each sample was compared to the standard 
curve to determine cell number per well.    
 
3-Dimensional Spheroid Invasion Assays 
 Spheroids were formed and grown in a three-dimensional collagen matrix 
as previously described (Smalley et al, 2006).  Melanoma cells were plated in 
triplicate on 1.5% Noble agar and incubated for 1-2 days.  Spheroids were 
collected and centrifuged to remove media, resuspended in 2.5 mg/ml bovine 
dermal collagen (Pure Col, INAMED, Leimuiden, Netherlands) containing RPMI 
+ 10% FBS, and overlaid on a pre-solidified layer of the same collagen solution.  
The collagen/spheroid suspension was allowed to solidify for 1 hour, then 
overlaid with RPMI + 10% FBS.  Spheroid growth and invasion into the collagen 
was monitored by microscopy for up to 6 days after implantation.  Invasion from 
spheroids was quantified using Image J software.  The ratio of the outer, invasion 
radius (R2) to the inner core radius (R1) was measured in triplicate for each 
spheroid. 
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Immunoblot and Antibodies 
 Cells were lysed in 20 mM Tris pH 8.0, 2% SDS, and 10 mM 
dithiothreitol and boiled for 10 min.  Protein concentration was determined using 
the DC Protein Assay (Bio-Rad, Hercules, CA, USA) and gel loading was 
normalized for total protein.  Membranes were blocked with 5% (w/v) nonfat 
milk and washed in phosphate-buffered saline (PBS) with 0.1% (v/v) Tween-20.  
Primary antibodies were diluted in 5% BSA-containing PBS/ 0.1% Tween and 
recognized ERK1/2 (Cell Signaling, #9102), phospho-ERK1/2 (Sigma, M8159), 
CCND1 (Upstate, #06-137), LEF-1 (Santa Cruz, sc-81470), MLANA (Santa 
Cruz, sc-28871), ITGB3 (Santa Cruz, sc-14009), CCNE2 (Cell Signaling, #4132), 
DUSP4 (Santa Cruz, sc-1200), p21 (Cell Signaling, #2946), and TBP (Santa Cruz, 
sc-273). Horseradish peroxidase secondary antibodies (Jackson ImmunoResearch) 
were diluted 1:5000 in PBS + 0.1% Tween with 5% nonfat milk and visualized 
using enhanced chemiluminescence (Perkin-Elmer). 
 
3’UTR Luciferase Reporter Assays 
 Melanoma cells were co-transfected with mimics and 3’UTR luciferase 
reporter constructs (Switchgear Genomics, Menlo Park, CA, USA) for various 
genes using Dharmafect Duo (Dharmacon, Thermo-Fisher).  20,000 cells per well 
were plated onto opaque 96-well plates (Becton Dickinson, 353296) 24 hours 
prior to transfection with 100 nM 3’UTR luciferase reporter and 5-20 nM mimic.  
Luminescence was analyzed 24 hours later by adding 100 µL Steady-Glo 
luciferase reagent (Promega) to each well, incubating for 30 minutes, and 
measuring luminescence on a Beckman Coulter DTX 880 microplate reader. 
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RESULTS 
 
MicroRNA Profiling in Melanocyte and Melanoma Lines. 
Microarray profiling was used to identify miRNAs deregulated in 
melanoma cells and responsive to constitutive B-Raf V600E signaling in 
melanoma.  We analyzed miRNA expression levels in two primary melanocyte 
cell lines (NHEM2493, HEM-LP) and six melanoma cell lines derived from either 
primary vertical growth phase tumors or metastatic tumors from the same patient 
(WM115, WM278, WM793, WM239A, WM1617, and 1205Lu).  In order to 
distinguish miRNAs specifically deregulated as a result of constitutive B-
Raf/MKK/ERK signaling, we also assessed miRNA expression levels in the six 
melanoma lines treated with 10 µM MKK1/2 inhibitor (U0126) or DMSO vehicle 
control (Figure 2.1A).  All six melanoma cell lines have been previously reported 
to carry the B-Raf V600E mutation and express high levels of phospho-ERK1/2, 
which is attenuated by U0126 treatment (Figure 2.1B).  By including six 
melanoma cell lines in the analysis and restricting accepted targets to those with a 
consistent deregulation and drug response across the lines, we increased the 
likelihood of identifying targets with biological relevance.   
Microarray experiments on all 20 samples and a biological replicate were 
carried out using custom Agilent miRNA microarrays (Thermo Fisher miRBase 
9.0, probes in triplicate).  The dye-labeled Thermo Fisher miRNA Reference 
Probe Set was added to each sample prior to hybridization and served as a 
universal reference control allowing more accurate comparison of both features 
within a single array and features across many arrays.  Combined with other 
26
MelanomasMelanocytes
Untreated Cell Lines Treated Cell Lines
Melanomas
DMSO U0126
MicroRNA Expression Profiling
A
B
U0126: - + - + - + - + - + - +
W
M1
15
W
M2
39
A
W
M2
78
W
M1
61
7
W
M7
93
12
05
Lu
pp-ERK1/2
ERK1/2
Figure 2.1 Microarray profiling strategy for identification of B-RafV600E 
regulated miRNAs.
(A)  Diagram depicting the strategy for identification of B-RafV600E regulated 
miRNAs in melanoma cells.  (B)  Immoblot analysis of phospho-ERK1/2 and 
total ERK1/2 levels in melanoma cell lines treated with 0.1% (v/v) DMSO or     
10 µM U0126 for 24 hours.  
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spike-in controls and background controls, this system efficiently normalized for 
variability in sample labeling efficiency, hybridization, and baseline fluorescence.  
Normalization was carried out as described and log10 values for all 18,800 data 
points were generated (Supplemental Table 1).  Of the 470 microRNAs profiled, 
171 miRNAs had “Is-Present” p-values <0.05 in fewer than 10 of the 40 samples 
and were therefore excluded from further analysis (Supplemental Table 2). 
Upon comparison of the average melanocyte and melanoma cell line 
intensities, we identified over 30 miRNAs significantly deregulated by 1.5 fold or 
greater with p-value < 0.05 in the melanoma lines (Figure 2.2).  Additionally, 27 
miRNAs were deregulated by at least 1.3 fold (p-value <0.05, Figure 2.3).    We 
verified the expression of a large subset of these miRNAs using real time qRT-
PCR, and Figure 2.4 demonstrates the high degree of correlation that was 
observed between the microarray and qRT-PCR data.  Along with validating the 
overall direction of deregulation for each miRNA, the qRT-PCR data also 
strikingly matched the exact expression pattern across all cell lines.  This strong 
confirmation of the microarray data added confidence to other small fold changes 
in the array data that were not validated and also demonstrated the effectiveness 
in normalization and accuracy provided by the Thermo Fisher Dharmacon 
platform. 
Previous studies on global miRNA expression in melanoma cell lines and 
biopsies generally lacked an overall correlation of changes between individual 
miRNAs.  However, they did show overlap between several miRNA families and 
the results from our screen were consistent with these previous reports.  One 
particular miRNA, miR-211, was consistently reported as down-regulated in 
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Figure 2.2 B-RafV600E regulates a large subset of miRNAs differentially 
expressed in melanoma cells.
Heat map representing the changes in miRNA expression between melanocyte 
(mcyte) and melanoma lines and untreated versus U0126 treated melanoma lines.  
The fold change in expression of combined biological replicates for each cell line 
is normalized to the average melanocyte expression or DMSO control and 
presented on a Log2 scale.  
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Figure 2.3 B-RafV600E regulates a small number of miRNAs 1.3 fold differ-
entially expressed between melanocyte and melanoma lines.
Heat map representing the expression of miRNAs changed 1.3 fold (p-value 
<0.05) between melanocyte and melanoma cell lines.   The fold change in expres-
sion of combined biological replicates for each cell line is normalized to the 
average melanocyte expression or DMSO treatment and presented on a Log2 
scale.  
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Figure 2.4 Real-time PCR validation of microarray data.
(A-E, K-O)  Relative miRNA expression across cell lines for array and qRT-PCR 
data.  Quantitative RT-PCR for select miRNAs was performed to assess the 
performance of  the microarray platform.  Expression in each cell line was 
normalized to the melanocyte average.  (F-J, P-T)  Percent change with U0126 
treatment for array and qRT-PCR analysis. Values represent the average +/-SEM 
from two biological replicates (array) or three technical replicates (qRT-PCR).     
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melanomas (Caramuta et al, 2010; Chen et al, 2010) and was found to be the most 
strongly repressed miRNA in our study.  Also, several let-7 family members, 
including let-7i, have been shown to be repressed in melanoma cell lines or 
biopsies (Caramuta et al, 2010; Chen et al, 2010; Schultz et al, 2008).  Caramuta 
et al also identified miRs-10b, 34a, 34b, 22, 125a, and 132 as down-regulated in 
primary or metastatic melanoma cell lines.  Among the most well studied miRNA 
families up-regulated in melanoma is miR-221/222 (Felicetti et al, 2008; 
Igoucheva et al, 2009; Sequina et al, 2009), which we also find to be increased in 
melanoma cells compared to melanocytes.  In our melanoma cell lines, we find a 
large number of the miR-17~92 family and cluster members induced by 1.3-1.5 
fold (miR-17-5p, miR-20a, miR-106b, miR-106a, miR-106b, miR-92b), and up-
regulation of various members of this family has been seen in several reports 
(Chen et al, 2010; Igoucheva et al, 2009).  We observed differentially expressed 
miRNAs in common between our dataset and those of previous studies in 
melanoma cell lines and biopsies, which suggested that our results likely reflect a 
number of miRNAs that are biologically important for melanoma.   
 
B-RafV600E Regulates Multiple Cancer-Associated MicroRNAs. 
In order to distinguish which deregulated miRNAs are potential targets of 
oncogenic B-RafV600E, we included the change in miRNA expression with 
U0126 treatment for each miRNA represented in Figure 2.2 and Figure 2.3.  Over 
half of all miRNAs that were deregulated by ≥ 1.5 fold in the melanoma lines 
demonstrated a consistent, reciprocal change in expression after 24 hour treatment 
with U0126.  Interestingly, a number of miRNAs were not differentially 
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expressed in the melanoma lines but displayed a strong response to the MKK1/2 
inhibitor (Figure 2.5).  Although treatment with the MKK1/2 inhibitor elicited 
only small changes in miRNA expression, we also validated these measurements 
using real time qRT-PCR and found that fold changes in expression were 
consistent, if not increased, when compared with microarray data (Figure 2.4F-J, 
P-T).  A previous study also demonstrated that treatment of HeLa cells with 
U0126 resulted in an approximately 20% increase in miR-17 and miR-20a, and a 
similar decrease in let-7, consistent with our findings in the melanoma cell lines 
(Paroo et al, 2009). 
Upon examination, many B-RafV600E miRNAs have not been well 
studied in melanoma but were previously linked to other cancers, where they were  
showed either oncogene or tumor suppressor functions.  Table 2.1 provides a 
summary of the known functions and targets of these miRNAs in other cancer 
types and diseases.  One of the most well studied oncogenic miRNA families is 
miR-17~92, which is over-expressed in many cancers and diseases and is 
associated with increased proliferation and tumorigenesis (J.T. Mendell, 2008).   
Conversely, both miR-34a and the let-7 family members are known tumor 
suppressors in many different cancers and have been strongly linked to 
suppression of proliferation involving key cell cycle regulatory genes (Roush et 
al, 2008; H. Hermeking, 2010).  Altogether, our microarray screen identified a 
large network of cancer-associated miRNAs regulated by oncogenic B-RafV600E 
signaling. 
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B-RafV600E-regulated miRNAs control cell proliferation and 3-dimensional 
invasion. 
 
 To determine whether the B-RafV600E miRNAs are functionally 
significant in melanoma, we examined the entire network of ~25 miRNAs for 
their effects on both cell proliferation and invasion.  Each miRNA was expressed 
in WM239A cells using a synthetic mimic oligonucleotide, and cell growth was 
analyzed using the colorimetric based WST-1 assay.  Fourteen of the B-
RafV600E miRNAs were capable of influencing cell proliferation, in a manner 
consistent with the direction of deregulation in the melanoma cells (Figure 2.6A).  
These included known repressors of proliferation (let-7i, miR-34a, miR-22), as 
well as miRNAs previously shown to induce proliferation and tumorigenicity 
(miR-17 family, miR-92/25).  Although the changes in cell growth upon miRNA 
expression were fairly modest when measured using the WST-1 assay, the effect 
on cell numbers is also apparent when assessing confluency of cells allowed to 
grow for several days after transfecting the miRNA mimic oligonucleotides 
(Figure 2.6B).  Cells treated with miRNAs previously characterized as growth-
suppressive (let-7i, miR-34a) showed less density at confluence when compared 
to lipid or non-targeting treated controls, whereas treatment with miRNAs 
characterized as growth-inducing (miR-106a, miR-92a) resulted in higher cell 
density at confluence. 
 We next screened the network of miRNAs for cell invasion using a three-
dimensional spheroid assay.  Spheroids were formed from melanoma cell 
suspensions and then embedded into semisolid collagen I, mimicking growth and 
invasion in an extracellular matrix with composition similar to of human dermis.  
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Figure 2.6  B-RafV600E miRNAs affect proliferation of melanoma cells.
(A) Relative change in cell growth with miRNA expression.  WM239A cells were 
transfected with 100 nM miRNA mimic, plated for WST-1 cell proliferation  
assay, and analyzed 24 hours later. Cell numbers at day 3 were normalized to cell 
numbers at the time of plating, and all values were normalized to lipid-treated 
controls.  NT, non-targeting.  Error bars represent the SEM from three indepen-
dent experiments.  (B)  Cell confluency with miRNA over-expression.  1x106 
WM239A cells were transfected with 100 nM miRNA mimic on 6 cm plates.  
Cells were grown for 4 days and then photographed using 4x magnification.   
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Upon expression of the various B-RafV600E regulated miRNAs, we observed 
striking changes in cell morphology as well as invasion into the surrounding 
collagen (Figure 2.7 and Figure 2.8).  miRNAs down-regulated by B-RafV600E, 
including  let-7i, miR-211, and miR-22, caused a decrease in overall invasion 
(Figure 2.9), suggesting their repression by B-RafV600E supports increased 
invasion in melanomas.  Surprisingly, miR-34a and miR-26a increased the overall 
radius of cells invading from the spheroid into the matrix (Figure 2.9), which was 
unexpected based on previously characterized tumor suppressor behavior and the 
decreased cell proliferation observed with miR-34a expression.  Screening the 
miRNAs up-regulated by B-RafV600E identified two families with strong 
influence on cell invasion, miR-17/20/106/93 and miR-221/2 (Figure 2.8).  
Members of these families induced by oncogenic B-RafV600E led to increased 
invasion into the surrounding collagen (Figure 2.9) and demonstrated a consistent 
phenotype between miRNAs sharing identical seed sequences.  Because B-
RafV600E regulates several families containing multiple miRNA members (let-7, 
miR-17/20/106/93, miR-92/25, miR-221/222), functional screening was mainly 
carried out using overexpression with miRNA mimics, in order to avoid 
complications from simultaneously inhibiting more than one family member.  
However, cells treated with miRNA inhibitors showed opposing effects on 
spheroid invasion, which validated the trends observed with the miRNA mimics 
(Figure 2.10).   
 Together, these results demonstrate that B-RafV600E suppresses multiple 
miRNAs which negatively regulate melanoma cell proliferation and/or invasion 
(let-7i, miR-34a, miR-22, miR-211) while simultaneously inducing other 
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Figure 2.9  Quantification of spheroid invasion with overexpression of 
B-RafV600E miRNAs.
Quantification of spheroid invasion for (A) B-Raf down-regulated miRNAs and 
(B) B-Raf up-regulated miRNAs.  For each spheroid,  the ratio of outer (R2) to 
inner (R1) radius was normalized to the control value.  Error bars represent SEM 
of three spheroids (each measured in triplicate).  Asterisks show experimental 
mimics which differed by a p-value <0.05. 
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Figure 2.10 miRNA inhibitors validate effects of select miRNA mimics on 
spheroid invasion.
Spheroid growth and invasion with miRNA inhibitors versus previous results with 
mimcs.  WM239A cells were transfected with 100 nM of inhibitor oligos (or      
50 nM each for miRs-26a and 26b) and incubated for 48 hours prior to setting up 
the three-dimensional spheroid assay.  
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miRNAs which support these oncogenic functions (miR-17/20/106/93, miR-
92/25, miR-221/222).  This establishes a strong role for miRNAs in the B-
RafV600E-mediated control of cell growth and invasion previously characterized 
in melanoma cells. 
 
Melanoma-associated genes are cross-regulated by B-RafV600E miRNAs. 
 Despite recent advances in miRNA target prediction algorithms and 
databases, identification of direct targets for a given miRNA or miRNA family 
still remains a challenging obstacle for the field.  In order to identify targets for 
the large subset of functional miRNAs regulated by B-RafV600E, we employed a 
filtering strategy based on a complimentary cDNA microarray dataset previously 
acquired in our lab which includes the cell lines treated with and without U0126 
in parallel to conditions used for the miRNA array profiling (Argast et al, 2009).  
A list of all possible gene targets was generated for each miRNA using 
TargetScan and miRanda prediction algorithms (Lewis et al, 2005; Enright et al, 
2004) and each list was crossed with the entire set of genes regulated by B-
RafV600E in the array dataset.  From these filtered predicted target lists, we 
identified genes important for melanoma cell growth, invasion, signaling, and 
overall biogenesis (Table 2.2).  Surprisingly, many of the potential genes were 
predicted to be targeted by multiple miRNAs, including those both induced and 
repressed by B-RafV600E.  
 To verify protein regulation by B-RafV600E, western blot analysis was 
performed on cells treated with two separate MKK1/2 inhibitors (Figure 2.11).  
Proteins verified as B-RafV600E targets were then analyzed for their responses to 
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Table 2.2  Potential Gene Targets of B-RafV600E miRNAs. 
Upregulated Genes Down-regulated miRs          Up-regulated miRs 
Cell Cycle/Proliferation   
CCND1 let-7, 34, 211 17/20/106/93 
CCNE2 34, 26, 30 17/20/106/93, 92/25 
CCNF let-7, 22, 211, 30 17/20/106/93, 7 
CDC6 26, 10 92/25 
NR4A2 34, 211, 30, 125a 17/20/106/93 
Adhesion/Invasion   
EPHA2 let-7, 26, 10, 125a  
HMGA2 let-7, 26, 211, 152, 125a 17/20/106/93, 92/25, 7 
ITGB3 let-7, 22, 211, 30, 10, 125a 221/222, 92/25, 7 
ITGA10 let-7, 34, 22, 26 221/222, 17/20/106/93, 7 
THBS1 let-7, 211, 125a 221/2, 7, 18, 19 
Signaling   
CD200 34, 211, 26, 152 17/20/106/93 
DUSP4 let-7, 211  
LEF1 34, 22, 26 17/20/106/93 
MYCN let-7, 34, 125a 17/20/106/93, 7, 19 
SH2B3 let-7, 22, 211, 30, 10, 152 17/20/106/93, 92/25, 7, 19 
Downregulated Genes Down-regulated miRs Up-regulated miRs 
Cell Cycle/Proliferation   
CDKN1A (p21) let-7, 22, 152 17/20/106/93 
CDKN1B (p27) 34, 152 221/222 
CDKN1C (p57) 34, 26 221/222, 92/25 
CHES1 let-7, 34, 22, 211 17/20/106/93, 92/25, 7, 18 
EZH1 let-7, 22, 152 221/222, 17/20/106/93, 18 
Adhesion/Invasion   
ANGPTL2 let-7, 211, 26, 152 221/222, 92/25, 7 
CYLD let-7, 34, 26, 30 221/222, 17/20/106/93, 92/25, 19 
EFBN2 211, 152, 125a 221/222, 17/20/106/93, 92/25, 19 
PTEN 22, 26, 10, 152, 125a 17/20/106/93, 92/25, 18, 19 
TIMP2 22, 211, 30, 125a 221/222, 17/20/106/93, 18, 19 
Signaling   
DKK3 let-7 92/25, 7, 19 
ETS1 26, 10, 152 221/222, 92/25, 19 
IRS2 let-7, 30 92/25, 7 
MARCKS 34, 211, 30, 10 221/222 
PIK3R1 211 221/222, 17/20/106/93, 92/25 
Melanogenesis   
ADCY9 let-7, 152 17/20/106/93, 92/25, 7, 19 
EDNRB 30, 125a 92/25, 19 
KIT 34, 152 221/222, 17/20/106/93, 18, 19 
MLANA 26 92/25 
MLPH 34, 152 17/20/106/93 
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Figure 2.11  B-RafV600E miRNAs cross-regulate several proteins associated 
with melanoma.
Western blotting for several predicted targets upon miRNA overxpression identi-
fied proteins targeted by one or more B-RafV600E regulated miRNAs.   To 
identify possible direct targets of each miRNA, WM239A cells were transfected 
with 50 nM miRNA mimics and harvested 48 hours after transfection.  TBP 
(TFIID) served as a loading control for all samples.  Underlined miRNAs indicate 
family members with identical seed sequence and which are likely to share similar 
targets.        
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miRNA expression.  Several proteins were repressed upon treatment with mimics 
for one or more miRNAs that were predicted to directly target the mRNA 3’UTR 
of the corresponding gene (Figure 2.11).  Interestingly, proteins were not only 
targeted by multiple co-regulated miRNAs, but also by those oppositely regulated 
by B-RafV600E.  3’UTR luciferase reporter assays for CCND1, ITGB3, and 
CCNE2 confirmed that both induced and repressed miRNAs can directly target 
these genes via the 3’UTR (Figure 2.12).  
 
B-RafV600E miRNAs work combinatorially to control cellular invasion. 
 The strong overlap in targets and functions suggested that B-RafV600E 
miRNAs might work cooperatively to regulate gene expression and/or function in 
melanoma cells.  To test this, we co-expressed miRNA mimics in various 
combinations and screened them for effects on spheroid invasion and target 
protein levels.  Combining invasion-suppressive let-7i with either miR-211 or 
miR-22, which were also capable of inhibiting invasion, led to further reduction 
of cell invasion in the spheroid (Figure 2.13A,C).  In contrast, combining each of  
these miRNAs with miR-34a, which by itself showed a slightly increased 
invasion, had little effect (Figure 2.13B).  This indicates that the enhanced effects 
of combining miRNAs is sequence specific, and not a general response to 
increased levels of miRNA transfected into the cells. 
 While these experiments demonstrated that miRNAs work combinatorially 
in suppressing invasion, no combinatorial targeting effect was observed towards 
CCND1 or ITGB3 proteins (Figure 2.14) or 3’UTR luciferase activity (Figure 
2.15).  In both assays, the protein and 3’UTR activity levels were reduced to the 
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Figure 2.12  Multiple B-RafV600E miRNAs can directly target the same 
3’UTR.
3’UTR luciferase reporter assays validate CCND1, ITGB3, and CCNE2 as direct 
targets of multiple B-RafV600E miRNAs.  The 3’UTR luciferase reporter for 
each gene was co-transfected with 20nM mimic for each possible targeting 
miRNA and a non-targeting (NT) miRNA that is regulated by B-RafV600E but 
does not have a binding site within the given 3’UTR.  Luciferase was analyzed 24 
hours post transfection, and values were normalized first to the NT miRNA and 
then to an identically treated GAPDH 3’UTR reporter.  Error bars represent the 
SEM of triplicate measurements.
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Figure 2.13  Co-expression of miRNAs augments suppression of spheroid 
invasion.
(A) Spheroid growth and invasion with expression of individual and combinations 
of miRNA mimics.  WM239A cells were transfected with 50 nM each (100 nM 
total) miRNA mimics.  24 hours post transfection, cells were plated onto agar and 
spheroid were allowed to form for 48 hours prior to implantation into collagen.  
Photographs represent growth and invasion 3 days after implantation. (B) Quanti-
fication of spheroid invasion.  For each spheroid,  the ratio of outer (R2) to inner 
(R1) radius was normalized to the let-7 value.  Error bars represent SEM of three 
spheroids, each measured in triplicate.
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Figure 2.14  miRNA mimic combinations do not have additive effects on 
ITGB3 or CCND11 protein levels.
Western blotting for CCND1 and ITGB3 upon expression of various combina-
tions of miRNAs.  WM239A cells were transfected with 50nM each (100nM 
total) miRNA mimics and harvested 48 hours post transfection.  Brackets indicate 
lanes where either the individual or both combined miRNAs expressed directly 
target the protein, and asterisks indicate lanes where only one of the miRNAs in 
the combination targets the protein.  
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Figure 2.15  miRNA mimic combinations do not show additive effects on 
3’UTR luciferase reporter activity.
3’UTR luciferase reporter assays do not show additive effects upon expression of  
multiple direct targeting miRNAs.  The 3’UTR luciferase reporter for each gene 
was co-transfected with 10nM each (20nM total) mimcs for CCND1 and 5nM 
each (10nM total) mimics for ITGB3, as well as the same amounts of a non-
targeting (NT) miRNA that is regulated by B-RafV600E but does not have a 
binding site within the given 3’UTR.  Luciferase was analyzed 24 hours post 
transfection, and values were first normalized to the NT miRNA and then to an 
identically treated GAPDH reporter.  Error bars represent the SEM of triplicate 
measurements.
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levels seen with the miRNA which most strongly targeted the gene, with no 
additional repression observed.  In these combinations, individual miRNAs were 
still capable of targeting their respected non-overlapping proteins (Figure 2.14), 
suggesting that each mimic was successfully incorporated and functional in the 
cells.  Therefore, the observed combinatorial effects on invasion were likely a 
result of the targeting of different genes within the invasion pathway rather than 
their convergence on individual, overlapping genes. 
 
DISCUSSION 
 
In this study, we identified a network of over 25 miRNAs controlled by 
oncogenic B-RafV600E signaling in melanoma cells.  By investigating both the 
targets and functions of each miRNA within the B-RafV600E network, I was able 
to establish global miRNA regulation as a novel molecular mechanism by which 
B-Raf/MKK/ERK signaling influences gene expression and cellular growth and 
invasion.  Several key melanoma genes were validated as direct targets of B-
RafV600E miRNAs, including novel protein targets of the B-Raf/MKK/ERK 
pathway in melanoma such as ITGB3, CCNE2, MLANA, LEF-1, and DUSP4.  
Previously, CCND1 (cyclin D1) was shown to be regulated by oncogenic B-Raf 
in melanoma through enhanced promoter activity (Bhatt at el., 2005).  Here, I 
identified a second, post-transcriptional mechanism by which B-RafV600E 
controls CCND1 levels, involving the regulation of multiple CCND1-targeting 
miRNAs.  Functional screening by cell growth and three-dimensional invasion 
assays revealed that miRNAs also play an important role in the B-RafV600E 
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supported growth and invasion phenotypes in melanoma cells.  Altogether, 
miRNAs serve as important molecular components in various aspects of B-
Raf/MKK/ERK mediated melanoma biogenesis (Figure 2.16). 
This study represents one of the first reports of global miRNA expression 
reprogramming as a result of a single oncogenic mutation pathway in a cancer or 
disease.   A recent study investigated the correlation of B-Raf mutational status 
with miRNA expression patterns in melanoma, but identified only three miRNAs 
differentially expressed in B-RafV600E tumors versus wild type tumors 
(Caramuta et al, 2009).  Another recent study profiled ovarian carcinomas for 
correlations in miRNA expression and BRCA1/2 mutations but were unable to 
identify any miRNAs which differentiated BRCA1/2 mutated and wild type 
carcinomas (Lee et al, 2009).  A major caveat of previous profiling experiments 
attempting to associate mutational status with either mRNA or miRNA regulation 
has been the methodologies used, of comparing tumors harboring or lacking the 
specific mutation.  Tumors that are wild type for a specific protooncogene often 
harbor an oncogenic mutation in another gene, sometimes within the same 
pathway, which results in similar pathway alterations.  This is especially true for 
melanomas, where a high percentage of tumors lacking oncogenic B-Raf 
mutations contain activating mutations in N-Ras (Alsina et al, 2003; Gorden et al, 
2003).  Additionally, tumor specimens generally represent a heterogenous cell 
population including stromal cell types such as fibroblasts, immune cells, and 
endothelial cells.  Cellular heterogeneity may lead to variation between tumor 
samples as well as interfere with the analysis of cancer cell-specific miRNA 
expression.  In order to overcome these obstacles, our microarray profiling 
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strategy involved first comparing B-RafV600E positive melanoma cell lines to 
primary, untransformed melanocyte cells and then using a small molecule 
inhibitor to directly examine miRNAs responsive to B-Raf/MKK/ERK signaling.  
This approach enabled us to effectively identify a large number of miRNAs 
directly regulated by this oncogenic pathway and therefore generate a B-
RafV600E miRNA signature for melanoma cells.  
The discovery of such a large network of co-regulated miRNAs raises the 
possiblity that they might not act independently, but rather interact or compliment 
one another to regulate gene expression and function.  Most studies of miRNA 
functions in cancer generally focus on a one miRNA or a specific miRNA family.  
However, the majority of cancers profiled so far undergo fairly substantial 
miRNA expression reprogramming and have a significant number of miRNAs 
simulataneously dysregulated.  Although previous studies have identified 
differentially expressed miRNAs in melanomas, the functional role of these 
miRNAs in melanoma has been poorly studied.   
In this study, I assessed the functional effect of each B-RafV600E-
regulated miRNA on cellular proliferation and invasion and ultimately identified 
roles for a large number of regulated miRNAs.  The results were consistent with 
the few previous reports available on let-7i and miR-221/222 in melanoma 
(Schultz et al, 2008; Felicetti et al, 2008) and also for the first time demonstrated 
a functional role specifically in melanoma for several well established cancer-
associated miRNAs, including miR-34a and miR-17~92 family/cluster members.  
Also, novel phenotypes for miR-211, miR-22, and miR-26a in cancer were 
discovered.  I further showed that co-expression of multiple miRNAs regulated by 
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a common pathway can lead to enhanced functional effects, providing a rationale 
for the regulation of such a large number of miRNAs by a single oncogenic 
mutation in B-Raf. 
Most genes exhibit relatively long 3’UTR regions and subsequently 
contain binding sites for many different miRNAs, and cases where multiple 
miRNAs are capable of binding and regulating a single gene 3’UTR have recently 
been reported (Borgdorff et al, 2010; Wu et al, 2010).  However, due to the 
difficulty in identifying direct gene targets of miRNAs, most studies tend to report 
just one or a few direct gene targets for a given miRNA.  Consequently, there 
have been virtually no reports of overlapping gene targets for miRNAs co-
regulated in a cancer or disease.  Here, we report for the first time several 
instances where co-regulated miRNAs can directly target the 3’UTR of the same 
gene, each leading to a reduction in protein expression.  Surprisingly, a subset of 
these (CCND1, CCNE2, LEF-1, ITGB3) are direct targets for both induced and 
repressed miRNAs suggesting a highly complex interaction of co-regulated 
miRNAs may contribute to overall 3’UTR regulation.  The identification of 
overlapping gene targets and functions of co-regulated miRNAs highlight the 
significance of analyzing entire miRNA networks in cancer due to the potential 
cross-regulation of both gene targets and functions. 
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CHAPTER III 
 
B-RafV600E Controls the Axon Guidance Gene, Semaphorin 3C, in 
Melanoma 
 
 
INTRODUCTION 
 
 B-RafV600E regulates many diverse functions in melanoma, suggesting 
that this oncogene controls a large cohort of genes involved in different molecular 
functions.  Recently, our laboratory reported a microarray profiling study which 
identified gene groups regulated by B-Raf/MKK/ERK signaling in melanoma cell 
lines (Argast et al, 2009).  Axon guidance family members comprised a set of 
genes which were strongly induced in response to MKK1/2 inhibitors, indicating 
that genes which regulate this process are repressed by signaling downstream of 
B-RafV600E in melanoma.  Our laboratory went on to show that plexin B1 was 
among the axon guidance genes found to be repressed by B-Raf signaling, and 
demonstrated a novel tumor suppressor role for this receptor in cancer (Argast et 
al, 2009).  In contrast to numerous studies in other cancer types, there have been 
only a handful of reports on the characterization of axon guidance proteins in 
melanoma.   
 Other axon guidance genes which appeared in our screen were semaphorin 
ligands for plexin receptors.  Semaphorin 3C (sema3C) displayed the highest 
average fold induction following MKK1/2 inhibition, and showed a consistent 
response across each of eight melanoma cell lines tested (Figure 3.1).  In order to 
further enhance our understanding of molecular mechanisms underlying B-
RafV600E mediated oncogenesis, and to address the overall role of axon guidance 
molecules in melanoma, I examined the regulation of sema3C by B-
Raf/MKK/ERK signaling and the functional role for this ligand in melanoma. 
 In this chapter, I discovered that sema3C is suppressed in melanoma lines 
compared to melanocytes, as a consequence of constitutive activation of the B-
Raf/MKK/ERK pathway.  I showed that multiple transcription factors (TFAP2A, 
ATF3, and JUN) are similarly regulated by this pathway and are required for the 
induction of sema3C by MKK1/2 inhibition, revealing a transcriptional 
mechanism for B-RafV600E-mediated repression of sema3C expression.  
Analyses in both primary and metastatic melanoma cell lines using strategies for 
sema3C inhibition or over-expression identified a novel role for this semaphorin 
in melanoma cell migration and invasion, as well as tumor growth and metastasis.  
These studies revealed for the first time that sema3C functions as a tumor 
suppressor in melanoma.  Interestingly, opposite effects on cell migration and 
invasion were observed between primary and metastatic lines upon the inhibition 
or elevation of sema3C expression.  A similar reciprocal control of cellular 
responses to sema3C was observed in tumor xenografts, where sema3C acted as 
either a tumor suppressor or inducer in a manner correlated with its expression in 
either primary or metastatic melanoma cells.  Western blotting revealed that the 
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Figure 3.1  Microarray analysis indicates repression of sema3C by 
B-Raf/MKK/ERK signaling in melanoma cell lines.
Microarray intensities, normalized by robust multiarray averaging (RMA), show 
that sema3C expression is induced by U0126 treatment (10 µM, 24 hr) in cell 
lines derived from tumors in different stages.
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sema3C ligand might signal through pathways activated by protease-activated 
kinase (PAK), which have not been previously associated with class 3 semaphorin 
receptor complexes.  Altogether, this study identified sema3C as a molecular of 
target of the B-Raf/MKK/ERK pathway which demonstrates stage-specific tumor 
suppressor and oncogenic roles in melanoma.    
  
METHODS 
 
Cell Lines 
Primary melanocyte cells (NHEM2493) were purchased from Cambrex 
Bio Sciences (Walkersville, MD, USA) and were grown in Medium154 with 
Human Melanocyte Growth Supplement (Cascade Biologics, Portland, OR, 
USA).  Melanoma cell lines were a gift from Meenhard Herlyn, Wistar Institute 
(Hsu et al, 1999) and were cultured in RPMI (Invitrogen) supplemented with 10% 
FBS (Gemini, West Sacramento, CA, USA) and penicillin-streptomycin (100 
U/mL).  All cell lines were maintained at 37°C and 5% CO2. 
 
Expression Constructs 
Transient and stable expression constructs for sema3C were generated by 
subcloning the sema3C cDNA cassette from a pBluescriptR cDNA clone (Open 
Biosystems, cat# MHS1010) and inserting it into pCMV-Myc (Clontech 
Laboratories, Inc.) or a GFP-expressing retroviral vector  pREX-GFP (a gift of 
Xuedong Liu, University of Colorado, Boulder).  An adenovirus strain for the 
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expression of constitutively active mutant MKK1 (‘R4F’Δ(32-51)/S281E/S222D) 
was a gift of Dr. Andrey Sorokin, Medical College of Wisconsin.     
 
Drug Treatment 
 In order to inhibit MKK1/2 signaling, melanoma cells were treated with 
up to 10 µM U0126 (Promega) or up to 3 µM PD184352 (a gift from Pfizer, Ann 
Arbor, USA), and 0.1% v/v dimethylsulfoxide (DMSO) as a vehicle control.  
Cells were treated for 24 hr unless otherwise noted.  Transcription was inhibited 
by treating cells with 10 mg/mL actinomycin-D (Sigma) and incubating for 2 hr 
prior to the addition of U0126 or DMSO carrier. 
 
Immunoblotting 
 Cells were lysed in 20 mM Tris pH 8.0, 2% w/v SDS, and 10 mM 
dithiothreitol, and boiled for 10 min.  Protein concentrations were measured using 
the DC Protein Assay (Bio-Rad, Hercules, CA, USA) and gel loading was 
normalized to total protein.  Membranes were blocked by incubation with 5% w/v 
nonfat milk and washed in phosphate-buffered saline (PBS) with added 0.1% v/v 
Tween-20.  Primary antibodies were diluted in 5% w/v BSA dissolved in PBS + 
0.1% v/v Tween-20, and were specific for semaphorin3C (R&D Systems, 
AF1728), ERK1/2 (Cell Signaling, #9102), phospho-ERK1/2 (Sigma, M8159),  c-
Jun (Santa Crauz, sc-45), ATF3 (Santa Cruz, sc-188), TFAP2A (Santa Cruz, sc-
184), plexin A1 (Chemicon, AB9602), plexin A2 (Santa Cruz, sc-25640), NRP1 
(Santa Cruz, sc-5541), NRP2 (Santa Cruz, sc-5542), ITGB1 (Santa Cruz, sc-
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8978), CRMP2 p-Ser522 (ECM Biosciences, #CP2191), CRMP2 p-Thr555 (ECM 
Biosciences, #CP2251), GSK3β p-Ser9 (Cell Signaling, #9323), CDK5 (Santa 
Cruz, sc-173), LIMK1 p-Thr508/505 (Santa Cruz, sc-28409-R), Cofilin p-Ser3 
(Cell Signaling, #3311), PAK p-Thr423/Thr402 (Cell Signaling, #201), β-tubulin 
(Upstate, #05-661), and TATA binding protein (TBP, Santa Cruz, sc-273). 
Horseradish peroxidase secondary antibodies (Jackson ImmunoResearch) were 
diluted 1:5000 in PBS + 0.1% v/v Tween with 5% w/v nonfat milk and visualized 
using enhanced chemiluminescence (Perkin-Elmer). 
 
qPCR 
 Total RNA was isolated from cells and eluted in 40 µL H2O using the 
RNeasy kit (Qiagen).  For cDNA synthesis, 1.0 µg of RNA was reverse 
transcribed using the SuperScriptIII system (Invitrogen) with random hexamer 
primers according to manufacturer’s protocol.  PCR was performed using 2.0 µL 
cDNA per reaction with primers specific for sema3C (5’-GGATCAGGACTCC 
CTGTGAA-3’, 5’-TTTTACCCAACTGGGAAAGG-3’) or TBP (5’-AGTTTTCT 
CCCTCAAACCAAG, 5’-CGGGAAGGGGCATTATTTG-3’).   
 
RNAi Knockdown 
 The levels of sema3C, c-Jun, ATF3, or TFAP2A were reduced by 
transfecting cells in suspension with SmartPool RNAi or a non-targeting control 
(Dharmacon Thermo Fisher, Lafayette, CO, USA) using DMRIE-C reagent 
(Invitrogen).  For immunoblotting, cells were harvested 48 hr later.  Sema3C 
levels were found to be reduced for at least 7 days after the initial transfection. 
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 Transwell Migration 
 A total of 50,000 cells (WM239A) or 30,000 cells (WM115) in serum-free 
RPMI were added to Transwell membrane chambers (Falcon 253097) and placed 
in a 24-well plate containing RPMI + 10% FBS as the bottom chamber 
chemoattractant.  After 24 hr, cells were removed from the bottom of the 
membrane and those remaining on top were trypsinized and counted with a 
hemacytometer.  For a duplicate chamber, cells were removed from the top 
membrane and those on the bottom were fixed in methanol, stained with 
hematoxylin, and manually counted under a microscope.  The percent of migrated 
cells was determined as the ratio of cell number from the bottom membrane to top 
membrane. 
 
Spheroid Assay 
 Spheroids were formed and grown in a three-dimensional collagen matrix 
as previously described (Smalley et al, 2006).  Melanoma cells were plated in 
triplicate on 1.5% w/v Noble agar and incubated for 1-2 days.  Spheroids were 
collected and centrifuged to remove media, resuspended in 2.5 mg/mL bovine 
dermal collagen (Pure Col, INAMED, Leimuiden, Netherlands) containing RPMI 
+ 10% FBS, and overlaid on a pre-solidified layer of the same collagen solution.  
The collagen/spheroid suspension was allowed to solidify for 1 hr, then overlaid 
with RPMI + 10% FBS.  Spheroid growth and invasion into the collagen was 
monitored by light microscopy for up to 6 days after implantation. 
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Mouse Xenografts 
 Stable cell lines expressing sema3C + GFP or GFP alone were trypsinized 
and resuspended in RPMI +10% fetal calf serum.  A volume of 100 µL (1x106 
total cells for WM239A, WM793, 1205Lu; 4x106 total cells for WM115) was 
injected intradermally into the right posterior flank of athymic nu/nu mice (NIH; 
female, 8-9 weeks old).  Bi-dimensional tumor measurements were taken for up to 
8 weeks and tumor volume was calculated as (π x short diameter2 x long 
diameter)/6.  At the end of the experiments, tumors were harvested, fixed 
overnight in 10% neutral buffered formalin (Sigma), and embedded and sectioned 
by the UCHSC Histopathology Laboratory. 
 
RESULTS 
 
Sema3C is repressed by B-Raf/MKK/ERK in melanoma cells. 
 Microarray analysis identified sema3C as the most strongly induced gene 
across several U0126-treated melanoma cell lines.  The microarray response was 
validated in 7 of 8 cell lines by Western blotting for sema3C protein levels in cells 
treated with U0126 as well as another MKK1/2 inhibitor, PD184352 (CI-1040, 
Figure 3.2).  To test whether sema3C is repressed in melanoma cells as a direct 
consequence of B-RafV600E signaling, I analyzed sema3C protein levels by 
Western blotting of lysates from melanoma cells, normal melanocyte cells, and 
melanocytes expressing a constitutive active (CA) form of MKK1.  Sema3C 
expression was elevated in the melanocytes compared to melanomas, and was 
strongly suppressed in melanocytes expressing CA-MKK1 (Figure 3.3A).  Also, 
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Figure 3.3  Sema3C expression inversely correlates with phospho-ERK1/2 
levels in melanocyte and melanoma cells.
(A) Sema3C is repressed in melanocyte cells expressing a constitutive active 
(CA) form of MKK1 which elevates levels of phospho-ERK1/2.  (UNT, 
untreated; GFP, expressing a GFP control vector)  (B) Dose response studies using 
two different MKK1/2 inhibitors demonstrate that sema3C expression is induced 
in a dose-specific manner directly corresponding to ERK1/2 inhibtion.  WM239A 
cells were treated with the indicated concentration of each inhibitor for 24 hr.
0 0.1 0.3 1.0 3.0 10 0 0.1 0.3 1.0 3.0 10
U0126 PD184352
uM:
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ppERK1/2
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β-tubulin
B
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sema3C expression increased in response to both MKK1/2 inhibitors, with dose 
response correlated with phospho-ERK1/2 inhibition (Figure 3.3B).  These results 
suggested that the B-Raf/MKK/ERK signaling pathway is sufficient for the 
repression of sema3C in melanoma cells. 
 
B-RafV600E suppresses Sema3C expression by co-repression of multiple 
transcription factors. 
 
 While the suppression of other class 3 semaphorins in cancer has been 
strongly linked to promoter hypermethylation (Tomizawa et al, 2001; Kusy et al, 
2005; Nair et al, 2007), time course studies showed that the induction of sema3C 
protein by U0126 in melanoma cells started within 8-12 hr of inhibitor treatment 
(Figure 3.4A).  The rate of induction was temporally inconsistent with the 
hypothesis that promoter methylation is the primary regulatory mechanism.  
Therefore, I focused on determining whether sema3C was transcriptionally 
induced upon MKK1/2 inhibition.  Treatment of cells with a transcriptional 
inhibitor, actinomycin-D, prior to U0126 addition completely blocked the 
induction of sema3C mRNA at 4 - 8 hr (Figure 3.4B) as well as the protein 
induction at 16 hr (Figure 3.4C).  This suggested that sema3C is mainly regulated 
by B-Raf/MKK/ERK through a mechanism involving transcriptional control.  In 
order to identify potential transcription factors involved in sema3C regulation, I 
analyzed the microarray dataset and identified genes that were either 2-fold 
induced or repressed by U0126, as well as associated with transcription factor 
activity (Table 3.1).  Analysis of potential transcription factor binding sites within 
the sema3C promoter revealed a number of sites for various factors that were also 
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Figure 3.4  Sema3C induction by U0126 occurs through a transcriptional 
mechanism.
(A) Timecourse analysis reveals that sema3C protein levels begin to increase after 
approximately 8-12 hr of U0126 treatment (10 µM) in WM239A cells.  (B) Semi- 
quantitative RT-PCR analysis demonstrates sema3C mRNA levels are induced by 
U0126 within 4 hr and further increased at 8 hr (lanes 1,2).  This induction is 
blocked by a 1 hr pre-treatment with 10 µg/mL actinomycin-D (Act-D, lanes 3,4).  
(C) Sema3C protein increases after 16 hr U0126 treatment (lanes 1,2) and is also 
blocked by pre-treatment with Act-D (lanes 3,4).
U0126 (hr): 0        2        4       8       12     16      20      24
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A
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Table 3.1  Transcription Factors Responsive to U0126 in Microarray Dataset 
Gene Symbol aFC with U0126  
Induced by U0126  
MAF + 4.3  
JUN + 2.9  
NFIL3 + 3.0  
TFAP2A + 2.3  
TRIM16 + 2.5  
ATF3 + 2.5  
ZEB2 + 2.4  
NR5A2 + 2.4  
SOX4 + 2.2  
NFKBIA + 2.2  
CITED1 + 2.1  
DDIT3 + 2.0  
Repressed by U0126 
ETV5 - 5.5  
EGR3 - 5.4  
MYC - 4.8  
ETV1 - 3.5  
FOSL1 - 3.4  
ETV4 - 2.8  
HEY2 - 2.7  
EGR1 - 2.3  
MYCN - 2.3  
NR4A2 - 2.3  
HEY1 - 2.1  
RCAN1 - 2.1  
NPAS2 - 2.0  
TFDP1 - 2.03  
   
aFC, Average fold change in microarray intensitiy across eight U0126-treated 
lines 
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induced by U0126 in the microarray dataset, including TFAP2A, ATF3, and c-
JUN (Figure 3.5).  Western blotting studies confirmed that each protein was 
induced by U0126, and individual knockdown of each factor nearly blocked the 
induction in sema3C levels completely, suggesting that each transcription factor is 
required for enhancing the transcription of sema3C in response to MKK1/2 
inhibition (Figure 3.6).  Thus, I have identified 3 separate transcription factors 
that were co-regulated with sema3C, and played a role in its transcriptional 
suppression by B-Raf/MKK/ERK in melanoma cells. 
 
Sema3C differentially regulates migration and invasion in melanoma cells.  
 Due to their role as axon guidance molecules, members of the 
semaphorin/plexin signaling family have been strongly implicated in the 
regulation of cancer cell migration and invasion.  Manipulating sema3C 
expression either by RNAi knockdown (Figure 3.7A) or transient and stable over-
expression (Figure 3.7B,C) resulted in differential effects on both migration and 
invasion in WM115 and WM239A melanoma cells.  Loss of sema3C expression 
by knockdown in WM239A, a cell line derived from a metastatic melanoma, 
resulted in increased Transwell migration, whereas over-expression reduced the 
percentage of migrating cells (Figure 3.8A,B).  This result is consistent with 
negative control of migration by sema 3C and correlates with sema3C repression 
in melanoma cells by B-Raf/MKK/ERK , where it may function to enhance 
cellular migration.  Interestingly, WM115 cells were generated from a primary 
melanoma tumor from the same patient as the WM239A metastatic line, but 
showed opposite effects on migration under the same conditions.  Sema3C 
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Figure 3.5  Transcription factors with sema3C promoter binding sites are 
induced by U0126 in melanomas.
Microarray intensities, normalized by robust multiarray averaging (RMA) show 
the expression of multiple transcription factors with potential binding sites within 
the sema3C promoter are induced by U0126 treatment (10 µM, 24 h) in         
melanoma cell lines.  
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Figure 3.6  RNAi knockdown of individual transcription factors blocks 
sema3C induction by U0126.
The induction of sema3C with U0126 (10 µM, 24 hr) is at least partially blocked 
in WM239A cells that have been transfected with 150nM of either TFAP2A, 
ATF3, or c-Jun RNAi 48 hr prior to treatment with U0126.
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Figure 3.7  Manipulation of sema3C levels in melanoma cell lines.
(A) Sema3C knockdown with 100nM SmartPool RNAi in the presence or absence 
of U0126 treatment (10 µM, 24hr) 48 hr post-transfection.  (B) Transient expres-
sion of sema3C using pCMV-sema3C (+) or empty pCMV (-) as control.  (C) Cell 
lines stably expressing sema3C (+) or empty pREX-GFP (-) as control.
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Figure 3.8  Sema3C differentially regulates migration in melanoma cell lines.
(A) Sema3C knockdown effects on transwell migration.  Cells were treated with 
100nM RNAi 48 hr prior to start of the assay.  (B) Effects of sema3C overexpres-
sion on transwell migration.  Cells were either transiently or stably expressing 
sema3C at the start of the assay.  Error bars represent the SEM of three indepen-
dent experiments.
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knockdown in this cell line caused a decrease in Transwell migration, and over-
expression led to an enhanced migratory capability (Figure 3.8A,B).   
 Differential effects between the WM115 and WM239A cell lines were 
also observed in a three-dimensional spheroid invasion assay.  By pre-forming a 
spheroid of cells and implanting it into a three-dimensional collagen matrix, the 
cells were surrounded by a microenvironment which better mimics the 3D 
environment of human skin tumors.  Similar to the effect on Transwell migration, 
expression of sema3C in WM239A resulted in a strong suppression of cellular 
invasion into the collagen (Figure 3.9).  Conversely, sema3C expression in 
WM115 cells induced a strong morphological change and increase in cellular 
invasion (Figure 3.9).  Therefore, two independent assays assessing cellular 
migration and invasion showed results that were in agreement with each other, 
and demonstrated an opposing influence of sema3C in the primary WM115 and 
metastatic WM239A cell lines.   
 
Sema3C re-expression in cells from primary and metastatic melanomas has 
divergent effects on xenograft tumor growth and lymph node metastases.  
   
 We next examined the influence of sema3C expression on in vivo tumor 
growth and metastasis using a mouse xenograft model.  Based on the inverse 
effects of sema3C on migration and invasion in the WM115 primary melanoma 
cell line compared to the WM239A metastatic melanoma cell line, we included 
WM793 (primary) and 1205Lu (metastatic) cell lines to the xenograft study in 
order to test a second pair of matched cell lines.  Although sema3C over-
expression blocked migration and invasion in the WM239A metastatic cell line, it 
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Figure 3.9  Sema3C differentially regulates spheroid invasion in melanoma 
cell lines.
A three-dimensional spheroid invasion assay reveals opposing effects on invasion 
between primary and metastatic melanoma cell lines.  Spheroids were formed 
from cells stably expressing sema3C and monitored for 6 days after implantation 
into the collagen matrix.
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enhanced the size of tumors formed from both WM239A and 1205Lu metastatic 
lines (Figure 3.10).  In contrast, over-expression of sema3C in both primary cell 
lines (WM115 and WM793) led to decreased tumor volume, despite a strong 
increase in in vitro cellular migration and invasion for WM115 cells (Figure 
3.10).  Typically, we never observe spontaneous metastasis of xenograft cells to  
lymph nodes or other organs, when these or other melanoma cell lines are 
administered subcutaneously into mice.  However, all mice harboring sema3C-
expressing WM115 cells showed one or more GFP-positive lymph nodes 
surrounding the site of cell injection, indicating that cells had metastasized (data 
not shown).  This correlated with the increased invasion observed with these cells 
in the three-dimensional spheroid assay (Figure 3.9).  Thus, sema3C results in 
opposite responses between primary and metastatic cell lines, which differs 
between responses of tumor size and metastasis in vivo and migration and 
invasion in vitro.  Thus, sema3C behaves as a tumor suppressor in primary cell 
lines, while increasing tumor size in metastatic cell lines.  Paradoxically, it 
increases cell invasion in spheroid culture while enhancing metastasis of 
xenograft cells in primary cell lines, while suppressing ccll invasion of metastatic 
cell lines.  Taken together, the results show that sema3C elicits complex responses 
which lead to either cancer suppressive or promoting phenotypes depending on 
the cellular context.   
 
A novel involvement of p21-activated kinase (PAK) in sema 3C signaling. 
 We hypothesized that the discrepancy in sema3C expression phenotypes 
between primary and metastatic cell lines involves differential activation of 
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Figure 3.10  Sema3C re-expression in primary and metastatic melanoma cell 
lines has divergent effects on xenograft growth. 
Tumor xenograft studies performed with cell lines stably expressing sema3C 
demonstrate differential responses between primary and metastatic melanoma 
lines.  Values report the average tumor volume and error bars represent SEM 
(WM115, n=3; WM239A, n=5; WM793, n=5; 1205Lu, n=4)
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downstream signaling effectors.  Although semaphorins were originally 
discovered in neurons as axon guidance regulators, multiple studies have shown 
they utilize many of the same receptors and downstream effectors to control cell 
migration in cancer (reviewed by Zhou et al, 2008).  Western blot studies were 
performed in WM115 and WM239A cells in order to determine whether NRP1/2 
and PLXNA1/2 receptors which are utilized by class 3 semaphorins are expressed 
in melanoma cell lines.  The results confirmed the expression of all four receptors 
in both WM115 and WM239A cells, with comparable expression between the two 
cell lines and only minor effects of MKK1/2 inhibitor on the level of NRP2 
(Figure 3.11).  Next, the effect of over-expressing sema3C on downstream 
effectors of these receptors was analyzed in WM115 and WM239A cells.  
Surprisingly, I observed no differences in expression or phosphorylation of these 
components between control vs sema3C expressing cells, in either cell line 
(Figure 3.12).  However, I observed large differences in the basal expression of 
most of these proteins between WM115 and WM239A cell lines, where all of the 
phosphorylated proteins tested (CRPM2, GSK3β, LIMK1) showed higher 
expression in WM115 cells compared to WM239A cells.  Because these 
phosphorylation events are generally linked to suppression of migration/invasion, 
their elevated levels in WM115 cells may reflect the diminished capacity of 
WM115  cells for invasion and migration compared to WM239A cells, as 
demonstrated above in spheroid invasion and Transwell migration assays (Figure 
3.9, Argast et al, 2009).  Also, the levels of integrin beta-1 (ITGB1), which is 
known to promote invasion, were increased in WM239A cells, correlating with 
enhanced migration and invasion of WM239A compared to WM115 cells.  Thus, 
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Figure 3.11  Melanoma cells express sema3C receptors and co-receptors.
Western blot analysis shows expression of PLXNA1/2 receptors and NRP1/2 
co-receptors in WM239A and WM115 cell lines.  Cells were treated with U0126 
(10µM, 24 hr) to indicate any regulation by B-Raf/MKK/ERK.  Asterisks indicate 
slightly higher loading of U0126 samples as indicated by TBP control blots.   
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Figure 3.12  Sema3C expression does not alter predicted downstream signal-
ing effectors.
Western blot analysis of cells stably expressing sema3C shows no change in 
protein or phosphorylation levels with sema3C expression, but does reveal differ-
ing basal expression between WM115 and WM239A cell lines.
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cellular components previously established as downstream effectors of class 3 
semaphorin pathways do not appear to be regulated by sema3C in melanoma 
cells, although they are differentially expressed between cell lines and may 
provide a variable underlying differential capacities for migration and invasion. 
I also analyzed phosphorylation of PAK and cofilin in cells where sema3C 
was knocked down by siRNA, simultaneous with U0126 treatment.  In both 
WM239A and WM115 cells, phospho-cofilin was induced upon MKK1/2 
inhibition and sema3C knockdown had no effect on this induction (Figure 3.13A).  
On the other hand, phospho-PAK(pThr423) was increased with U0126 treatment, 
and blocked by pre-treatment of both WM115 and WM239A cells lines with 
sema3C siRNA.  This suggested that sema3C might play a role in the B-
Raf/MKK/ERK regulation of PAK activity (Figure 3.13B).  Because no changes 
were seen in either phospho-LIMK or phospho-cofilin levels upon sema3C 
manipulation, the results suggested that any effects mediated by sema3C via PAK 
activation must involve signaling components downstream of PAK that are likely 
to be novel regulators, not previously associated with class 3 semaphorin 
signaling.   
 
DISCUSSION 
 
In this study, I discovered a novel repression of sema3C in cancer by 
showing that expression of this axon guidance gene is suppressed by oncogenic 
B-Raf signaling in melanoma cells.  Sema3C is among the lesser studied members 
of the class 3 semaphorin family, and aberrant expression of this particular 
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Figure 3.13  Sema3C knockdown blocks U0126 induction of phospho-PAK1, 
but not phospho-cofilin
Cells were transfected with 100 nM control or sema3C RNAi 48 hr prior to 
treatment with U0126 (10 µM, 24 hr) or DMSO control.  Cell lysates were probed 
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semaphorin has only been reported in prostate and metastatic lung cancer cells, 
where levels are found to be elevated (Blanc et al, 2010; Martin-Satue and 
Blanco, 1999).  Investigating the functional role of sema3C in melanoma using in 
vitro migration and invasion assays along with in vivo mouse xenograft studies 
revealed a novel tumor suppressor role for sema3C, as well as divergent 
functional effects between primary and metastatic cell lines.  This discovery of 
sema3C repression in melanoma and its tumor suppressive versus tumor 
promoting capabilities provides new insight regarding the role of axon guidance 
regulators in cancer, as well as a deeper understanding of the emerging concept 
that axon guidance genes show antagonistic pleiotropy in melanoma and other 
cancers.  
Consistent with its elevation in some cancers, sema3C has been previously 
associated with increased migration and invasion in both breast and prostate 
cancer cells (Esselens et al, 2010; Herman and Meadows, 2007).  Here, I also 
observed increased migration and three-dimensional spheroid invasion with 
sema3C expression in WM115 primary melanoma cells.  However, mouse 
xenograft experiments revealed a tumor suppressor role for sema3C in both 
WM115 and WM793 primary melanoma cells.  Because the xenografts from 
sema3C-expressing WM115 cells were smaller and metastatic, I speculate that 
sema3C might lead to events which reduce cell-cell adhesion and subsequently 
retard the ability of cells to form effective primary tumors, while enhancing the 
release of melanoma cells from the tumors and facilitating metastasis.  Therefore, 
repression of sema3C by B-Raf/MKK/ERK in WM115 cells might serve to 
enhance cell adhesion and promote tumor formation.  Although reduced sema3C 
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levels might also be expected to inhibit cell invasion, this attribute may not be as 
crucial for a primary tumor, and B-RafV600E signaling might bypass this effect 
in metastatic cells by enhancement of other invasion promoting pathways.   
 Conversely, the two metastatic melanoma lines showed increased tumor 
size upon sema3C expression, demonstrating a tumor promoting phenotype in 
these cells opposite to that seen in primary melanoma lines.  Opposing effects of 
sema3C on migration and invasion were also seen in metastatic WM239A cells 
compared to primary WM115 cells.  In WM239A cells, B-RafV600E suppression 
of sema3C should therefore enhance cell migration and invasion while 
simultaneously blocking its tumor-promoting effects.  Enhanced invasion might 
be expected to significantly promote the metastatic behavior of late stage 
melanoma cells, whereas the corresponding suppression of tumor size might not 
be as crucial and is likely bypassed in these cells through other mechanisms.   
Despite the dual role of sema3C in the overall formation and progression 
of melanoma, B-Raf/MKK/ERK suppression of sema3C is advantageous to both 
primary and metastatic lines by generating functional responses that appropriately 
benefit cells in either stage of cancer.  Previously in our lab, similar dual-
functional effects were observed with an axon guidance receptor, plexin B1. 
(Argast et al, 2009).  Plexin B1 suppressed tumor formation only in WM115 cells 
and suppressed cellular invasion only in WM239A cells.  Taken together with my 
studies, these findings suggest that stage-specific dual functionality may be a 
common attribute of axon guidance molecules in melanoma. 
 Such effects are not limited to cancer cells.  Dual functional responses to 
semaphorins and plexins is observed in other roles in development and neuronal 
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axon pathfinding, and therefore it is not surprising that many studies have 
documented their ability to have opposing effects on cellular functions within 
specific cell types (reviewed by Capparuccia and Tamagnone, 2009).  Because 
class 3 semaphorins require NRP co-receptors and signal through receptor 
complexes, a common mechanism emerging for bi-functional effects of class 3 
semaphorin involves differential expression of different co-receptors.  I observed 
no differences in expression of NRP1, NRP2, PLXNA1, or PLXNA2 between 
WM115 and WM239A cells, and subsequently analyzed other known 
downstream effectors.  Although several previously established axon guidance 
signaling pathway components were differentially expressed between WM115 
primary and WM239A metastatic melanoma lines, phospho-PAK(Thr423) was 
the only protein tested which demonstrated changes in response to sema3C 
knockdown or over-expression.  No changes in phospho-LIMK or phospho-
cofilin levels were seen in response to sema3C, suggesting this ligand signals 
through activated PAK in pathways not yet recognized as contributors to 
semaphorin-plexin mediated growth cone collapse and cancer cell behavior.  
Future studies are needed to investigate this intriguing observation for cell context 
dependent signaling of axon guidance receptors. 
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CHAPTER IV 
 
Conclusions and Future Directions 
 
DISCUSSION 
 
Although it has been many years since the B-RafV600E mutation was 
discovered in melanomas, the molecular basis for its regulation of diverse 
oncogenic phenotypes is still poorly understood.  A large effort has been made to 
understand the functional consequence of this single mutation, and many studies 
have linked B-RafV600E to cancer roles, including uncontrolled proliferation, 
evasion of apoptosis, angiogenesis, invasion, metastasis, and bypass of immune 
surveillance.  By applying a common profiling strategy to monitor changes in 
mRNA expression and miRNA expression, I have identified a very diverse set of 
miRNAs and genes which are regulated by B-RafV600E, and are functionally 
significant in events controlled in melanoma by this oncogene.   
 
Conclusions and future studies for B-RafV600E regulated miRNAs. 
Recently, miRNAs have emerged as important gene regulators that are 
often deregulated in cancer and other diseases.  My findings show that B-
RafV600E regulates a large network of miRNAs which share similar gene targets 
and functions.  My work identified an entirely new molecular mechanism by 
which B-Raf/MKK/ERK signaling may exert broad oncogenic phenotypes in 
melanoma.  In addition, my identification of this large network of co-regulated 
miRNAs allowed further exploration not only into the role of miRNAs in cancer, 
but also into basic unsolved questions concerning miRNAs and their complex 
control of gene regulation.  I found that miRNAs work together to augment 
effects on function, therefore emphasizing the importance for analyzing the entire 
network of differentially expressed miRNAs in any cell system.     
  This discovery that B-RafV600E controls a large network of microRNAs 
which share overlapping gene targets highlights the potential for complex gene 
regulation by this mechanism.  Although I was unable in this study to demonstrate 
enhanced repression of genes when simultaneously manipulating more than one 
miRNA, I believe that examining the effects of multiple miRNAs on multiple 
gene targets will yield new insight about how miRNAs control gene expression.  
One miRNA might bind the 3’UTR of a specific gene and dominate its repression, 
masking additive effects of multiple miRNAs.  However, it still remains to be 
tested whether loss of other targeting miRNAs may allow a dominating miRNA to 
further repress overall protein levels.  The ability of miRNAs which are either 
induced or repressed by oncogenic B-Raf to target the same mRNA 3’UTR 
suggests this hypothesis may be true, and can be tested by studies which over-
express one miRNA while simultaneously inhibiting another.  Furthermore, 
several genes targeted by B-RafV600E miRNAs are also known to be 
transcriptionally regulated by the same signaling pathway.  How transcriptional 
and miRNA dependent mechanisms each contribute to overall gene expression, 
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and in particular, whether the relatively small effects of miRNAs on protein 
expression are able to modulate the larger magnitude of protein changes 
responsive to transcriptional mechanisms, has been so far unexplored and would 
be a fascinating problem to study.   
B-RafV600E mutations are found in other cancer types, such as thyroid, 
ovarian, breast, and colon cancers (Davies et al, 2002).  Evidence is already 
emerging that shows miRNA expression can be oppositely regulated between 
cancers, and some miRNAs act as either an oncogene or a tumor suppressor based 
on the specific cell and cancer type (Reviewed by Zhang et al, 2007).  An 
interesting question raised by my findings in Chapter II is whether B-RafV600E 
regulates the same miRNAs in other cancer types besides melanoma.  This could 
be easily tested by surveying other cancer cell types for changes in responses of 
miRNA luciferase activity reporters, and treating these cells with MKK1/2 
inhibitors to monitor any response upon pathway inhibition.  Another interesting 
question is whether the functions of miRNAs regulated by oncogenic B-
Raf/MKK/ERK are the same across many cancer types.  I have previously shown 
that other cancer cell lines harboring the B-RafV600E mutation are able to form 
spheroids and invade into collagen, as seen with melanoma (Figure 4.1).  Such an 
assay could serve as a functional screen to interrogate effects of miRNA mimics 
and inhibitors observed in these cancers.  Such proposed studies are exciting, 
because they would establish for the first time whether miRNA regulation by B-
RafV600E serves as a global mechanism for oncogenesis and cancer progression. 
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Figure 4.1  Other B-RafV600E mutated cancers form spheroids. 
Spheroid invasion assays for other B-RafV600E positive cancer cell lines shows 
they can form spheroids and invade from the spheroid, demonstrating they can be 
functionally screening using the miRNA mimics and inhibitors. 
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Conclusions and future studies for the role of sema3C in melanoma. 
Our laboratory’s recent identification of axon guidance gene regulation by 
B-RafV600E through microarray studies prompted my investigations into 
sema3C, reported in Chapter III.  Global gene profiling using DNA microarrays 
represents a very powerful strategy to identify novel gene targets in cancers and 
other human diseases.  However, results from these global screens are not 
meaningful unless the targets identified are validated and shown to function in 
cellular control.  My identificaiton of a novel tumor suppressor function for 
sema3C, as well as my discovery of stage-specific dual functional roles for this 
ligand, has provided new insight into the role of axon guidance molecules in 
melanoma and a deeper understanding of how B-RafV600E supports melanoma 
progression.  
My studies provide another example where opposing functional effects are 
induced by a single axon guidance family member.  Class 3 semaphorins in 
particular are known to cause cell-type specific effects, including variously 
suppressing or promoting the migration and invasion of cancer cells.  However, 
the mechanisms for how they achieve these opposing effects are not well 
understood.  Here, I found striking differences in sema3C function between 
primary (WM115)  and metastatic (WM239A) melanoma cell lines.  I propose 
that one mechanism to explain dual functionality by semaphorins is their use of 
different receptor complexes to activate specific signaling downstream targets.  
Analysis of the DNA microarray dataset demonstrates there are many genes 
involved in cell adhesion, signaling, tumorigenesis, and other relevant molecular 
functions which are differentially expressed between the WM115 and WM239A 
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cell lines (Table 4.1) or else respond to U0126 treatment in one cell line but show 
less than 30% response in the other (Table 4.2).  These genes contain potential 
candidates that may explain the switch in sema3C functional responses, therefore 
future study of these genes are a first approach towards elucidating this 
mechanism.   
My investigations into the downstream signaling pathways activated by 
sema3C suggest that additional mechanisms besides those previously reported in 
neurons and other cancers might exist.  To address this possibility, future studies 
might be performed using proteomics and phosphoproteomics in order to globally 
examine signaling responses to sema3C and its potential receptors.  Phospho-
proteomics studies would be particularly important, due to the large number of 
tyrosine kinases and phosphorylation events controlled by axon guidance 
receptors.  Discovery of new signaling mechanisms would be beneficial to further 
understand the complex role of this ligand-receptor family in cancer and disease 
and could potentially aid in the development of therapeutics based on axon 
guidance family members.      
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Table 4.1  Genes differentially expressed between WM115 and WM239A
Symbol Title Fold increased, WM115
ADORA2B adenosine A2b receptor 4.44
ADRA2A adrenergic, alpha-2A-, receptor 3.38
AIM2 absent in melanoma 2 2.29
AK3 adenylate kinase 3 2.40
AK5 adenylate kinase 5 2.94
AKAP12 A kinase (PRKA) anchor protein (gravin) 12 2.08
ALDOC aldolase C, fructose-bisphosphate 8.52
ANGPT2 angiopoietin 2 22.50
APP amyloid beta (A4) precursor protein 2.07
BAGE B melanoma antigen 2.27
C8FW phosphoprotein 3.90
CAV1 caveolin 1, caveolae protein, 22kDa 2.07
CD36 CD36 antigen 112.42
CDH13 cadherin 13, H-cadherin (heart) 3.25
CRSP2 cofactor for Sp1 transcriptional activation 2.07
CTGF connective tissue growth factor 2.90
EDG2 endothelial differentiation, G-protein-coupled receptor 2.69
EDG7 endothelial differentiation, G-protein-coupled receptor 3.71
EPHA2 EphA2 2.15
F2R coagulation factor II (thrombin) receptor 2.31
FCGR2A Fc fragment of IgG, low affinity IIa, receptor for (CD32) 3.14
GAGE3 G antigen 3 8.67
GAGE4 G antigen 4 12.56
GAGE6 G antigen 6 12.42
GPR48 G protein-coupled receptor 48 2.23
GPRK5 G protein-coupled receptor kinase 5 2.21
HLA-B major histocompatibility complex, class I, B 3.99
HLA-B major histocompatibility complex, class I, B 3.78
HLA-C major histocompatibility complex, class I, C 3.63
HLA-DMA major histocompatibility complex, class II, DM alpha 15.52
HLA-DMB major histocompatibility complex, class II, DM beta 5.46
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 32.42
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 37.40
HLA-G HLA-G histocompatibility antigen, class I, G 2.32
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C 2.58
IGFBP3 insulin-like growth factor binding protein 3 3.76
IL12RB2 interleukin 12 receptor, beta 2 2.21
IL1R1 interleukin 1 receptor, type I 3.18
IL6R interleukin 6 receptor 2.81
IL6ST interleukin 6 signal transducer 2.13
ITGA5 integrin, alpha 5 2.03
ITGB8 integrin, beta 8 4.49
KDR kinase insert domain receptor 2.53
KITLG KIT ligand 2.67
LOX lysyl oxidase 2.42
LRP2 low density lipoprotein-related protein 2 2.67
MADH1 MAD, mothers against decapentaplegic homolog 1 2.18
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Table 4.1  Genes differentially expressed between WM115 and WM239A (cont.)
Symbol Title Fold increased, WM115
NCOA3 nuclear receptor coactivator 3 2.21
NDRG1 N-myc downstream regulated gene 1 2.24
NPC1 Niemann-Pick disease, type C1 2.21
NRCAM neuronal cell adhesion molecule 8.90
OPN3 opsin 3 (encephalopsin, panopsin) 4.93
PRKCD protein kinase C, delta 2.39
PTCH patched homolog (Drosophila) 2.31
PTN pleiotrophin 6.70
PTPN12 protein tyrosine phosphatase, non-receptor type 12 2.34
PTPRF protein tyrosine phosphatase, receptor type, F 2.86
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z 6.15
SFRP1 secreted frizzled-related protein 1 29.45
SNRK SNF-1 related kinase 2.02
SRI sorcin 2.36
SSX3 synovial sarcoma, X breakpoint 3 6.16
SSX4 synovial sarcoma, X breakpoint 4 5.89
STK4 serine/threonine kinase 4 2.04
SYNJ2 synaptojanin 2 5.51
TGFBI transforming growth factor, beta-induced, 68kDa 32.26
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 2.77
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 3.06
TNFRSF21 tumor necrosis factor receptor superfamily, member 21 3.12
WNT5A wingless-type MMTV integration site family, 5A 6.39
Symbol Title Fold increased, WM293A
CDK2 cyclin-dependent kinase 2 4.90
DTYMK deoxythymidylate kinase (thymidylate kinase) 2.03
F11R F11 receptor 2.46
FLRT2 fibronectin leucine rich transmembrane protein 2 2.57
GHR growth hormone receptor 7.17
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 4.04
IGFBP5 insulin-like growth factor binding protein 5 16.97
IGFBP7 insulin-like growth factor binding protein 7 2.03
INPP1 inositol polyphosphate-1-phosphatase 2.87
ITGA4 integrin, alpha 4 2.34
ITGB3 integrin, beta 3 2.43
LAMA2 laminin, alpha 2 2.33
LEPR leptin receptor 2.11
LOC169611 hypothetical protein LOC169611 2.54
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene 2.09
MAGEB2 melanoma antigen, family B, 2 2.11
MAP3K11 mitogen-activated protein kinase kinase kinase 11 2.06
MET met proto-oncogene(hepatocyte growth factor receptor) 3.33
MFI2 antigen p97 (melanoma associated) 2.35
MLANA melan-A 5.86
MPZ myelin protein zero 2.24
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Table 4.1  Genes differentially expressed between WM115 and WM239A (cont.)
Symbol Title Fold increased, WM293A
NBL1 neuroblastoma, suppression of tumorigenicity 1 3.51
NCAM1 neural cell adhesion molecule 1 2.08
NEO1 neogenin homolog 1 (chicken) 2.31
NRP1 neuropilin 1 2.28
NRP2 neuropilin 2 2.44
OSF-2 osteoblast specific factor 2 (fasciclin I-like) 26.63
PGRMC1 progesterone receptor membrane component 1 2.45
PKP4 plakophilin 4 2.14
PLAGL1 pleiomorphic adenoma gene-like 1 4.22
PRKAR1B protein kinase, cAMP-dependent, regulatory, type IB 2.04
RGS12 regulator of G-protein signalling 12 2.84
SCGF stem cell growth factor; lymphocyte secreted C-type 3.37
SEMA5A sema domain (type 1 and type 1-like) 5A 2.07
SILV silver homolog (mouse) 20.59
ST5 suppression of tumorigenicity 5 2.05
WSX1 class I cytokine receptor 2.64
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Table 4.2  Genes differentially induced by U0126 in WM115 and WM239A
Symbol Title WM115 FC WM239A FC
(Increased by U0126 in WM115 only)
CCL2 chemokine (C-C motif) ligand 2 3.70 1.16
CNTF ciliary neurotrophic factor 2.41 0.90
PPARG peroxisome proliferative activated receptor, gamma 2.53 1.09
(Decreased by U0126 in WM115 only)
ADORA2B adenosine A2b receptor 0.37 0.85
ALDOC aldolase C, fructose-bisphosphate 0.43 0.91
ANGPT2 angiopoietin 2 0.11 0.93
BAGE B melanoma antigen 0.49 0.96
CDK5R1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) 0.30 0.99
CTGF connective tissue growth factor 0.25 0.88
FOLH1 folate hydrolase (prostate-specific membrane antigen) 1 0.49 0.97
IGF1R insulin-like growth factor 1 receptor 0.49 0.78
IGFBP3 insulin-like growth factor binding protein 3 0.49 0.98
ITGB8 integrin, beta 8 0.37 0.80
ITPR1 inositol 1,4,5-triphosphate receptor, type 1 0.49 0.79
KITLG KIT ligand 0.47 0.81
LOH11CR2Aloss of heterozygosity, 11, chromosomal region 2,gene A 0.49 0.95
MADH7 MAD, mothers against decapentaplegic homolog 7 0.37 0.78
MET met proto-oncogene (hepatocyte growth factor receptor) 0.40 0.87
PTCH patched homolog (Drosophila) 0.47 0.89
SDCCAG16 serologically defined colon cancer antigen 16 0.48 0.89
SFRP1 secreted frizzled-related protein 1 0.22 0.78
SYNJ2 synaptojanin 2 0.43 0.91
VEGF vascular endothelial growth factor 0.29 0.93
WNT5A wingless-type MMTV integration site family, member 5A 0.20 0.90
XYLB xylulokinase homolog (H. influenzae) 0.45 0.75
(Increased by U0126 in WM239A only)
CAV2 caveolin 2 1.15 2.51
CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 1.10 2.95
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 1.04 2.37
GABRG2 gamma-aminobutyric acid (GABA) A receptor, gamma 2 1.27 2.02
L1CAM L1 cell adhesion molecule 1.23 3.57
LAMA2 laminin, alpha 2 1.21 2.68
MAP4K3 mitogen-activated protein kinase kinase kinase kinase 3 0.96 2.19
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 1.05 2.55
MDK midkine (neurite growth-promoting factor 2) 1.28 2.51
MYLK myosin, light polypeptide kinase 0.87 2.26
NOTCH1 Notch homolog 1, translocation-associated (Drosophila) 1.26 2.32
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.04 2.27
PNMA1 paraneoplastic antigen MA1 1.13 2.27
TGFB2 transforming growth factor, beta 2 1.17 7.60
TRIO triple functional domain (PTPRF interacting) 0.93 2.14
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Table 4.2  Genes differentially induced by U0126 in WM115 and WM239A
Symbol Title WM115 FC WM239A FC
(Decreased by U0126 in WM239A only)
ADAM12 a disintegrin and metalloproteinase domain 12 0.73 0.46
BRCA1 breast cancer 1, early onset 0.77 0.49
BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog 1.06 0.37
CDK2 cyclin-dependent kinase 2 0.75 0.40
CKS1B CDC28 protein kinase regulatory subunit 1B 1.04 0.46
CXADR coxsackie virus and adenovirus receptor 0.71 0.42
GAPDS glyceraldehyde-3-phosphate dehydrogenase, testis 0.85 0.41
GRIA2 glutamate receptor, ionotropic, AMPA 2 0.72 0.46
ICAM1 intercellular adhesion molecule 1 (CD54) 0.79 0.45
MC1R melanocortin 1 receptor 0.72 0.36
MCAM melanoma cell adhesion molecule 0.75 0.28
NR4A2 nuclear receptor subfamily 4, group A, member 2 1.02 0.46
NR4A3 nuclear receptor subfamily 4, group A, member 3 0.83 0.50
RRM1 ribonucleotide reductase M1 polypeptide 0.74 0.49
RXRG retinoid X receptor, gamma 1.01 0.42
STK18 serine/threonine kinase 18 0.79 0.39
STK6 serine/threonine kinase 6 1.08 0.40
TTK TTK protein kinase 0.74 0.32
FC; Fold change with U0126 treatment
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